<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2909222661
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FLOXACIN 500 MG COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CIPROFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        45.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>FLOXACIN is an antibiotic belonging to the fluoroquinolone family. The active substance is Ciprofloxacin.<br />Ciprofloxacin works by killing bacteria that cause infections. It only works with specific strains of bacteria.<br /><strong>Adults</strong><br />FLOXACIN is used in adults to treat the following bacterial infections:<br />Respiratory tract infections.<br />Long lasting or recurring ear or sinus infections.<br />Urinary tract infections.<br />Infections of the testicles.<br />Genital organ infections in women.<br />Gastro-intestinal tract infections and intra-abdominal infections.<br />Skin and soft tissue infections.<br />Bone and joint infections.<br />To treat infections in patients with a very low white blood cell count (neutropenia).<br />To prevent infections in patients with a very low white blood cell count (neutropenia).<br />To prevent infections due to the bacterium Neisseria meningitidis.<br />Anthrax inhalation exposure.<br />If you have a severe infection or one that is caused by more than one type of bacterium, you may be<br />given additional antibiotic treatment in addition to FLOXACIN.<br /><strong>Children and adolescents</strong><br />FLOXACIN is used in children and adolescents, under specialist medical supervision, to treat the<br />following bacterial infections:<br />Lung and bronchial infections in children and adolescents suffering from cystic fibrosis.<br />Complicated urinary tract infections, including infections that have reached the kidneys (pyelonephritis).<br />Anthrax inhalation exposure.<br />FLOXACIN may also be used to treat other specific severe infections in children and adolescents when<br />your doctor considered this necessary.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take FLOXACIN if you are:</strong><br />Allergic (hypersensitive) to the active substance, to other quinolone drugs or to any of the other<br />ingredients of FLOXACIN (see section 7).<br />Taking tizanidine (see Section 3: Taking other medicines).<br />You have ever had epilepsy.<br />Using it to treat infections that might get better without treatment or are not severe (such as throat<br />infections)<br />Using it to treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis;<br />Using it for preventing traveler&rsquo;s diarrhoea or recurring lower urinary tract infections (urine infections<br />that do not extend beyond the bladder)<br />Using it to treat mild or moderate bacterial infections unless other antibacterial medicines commonly<br />recommended for these infections cannot be used<br />Importantly, fluoroquinolones should generally be avoided in patients who have previously had serious<br />side effects with a fluoroquinolone or quinolone antibiotic.<br /><strong>Take special care with FLOXACIN<br />Before taking FLOXACIN</strong><br />Talk to your doctor before taking Floxacin<br />Tell your doctor if you:<br />Have ever had kidney problems because your treatment may need to be adjusted<br />Suffer from epilepsy or other neurological conditions<br />Have a history of tendon problems during previous treatment with antibiotics such as FLOXACIN<br />It should be used with special caution in the elderly, patients with kidney disease and those who have<br />had an organ transplantation because these patients are at a higher risk of tendon injury.<br />Since the use of a corticosteroid with a fluoroquinolone also increases this risk, combined use of these<br />medicines should be avoided.<br />Have myasthenia gravis (a type of muscle weakness)<br />Have a history of abnormal heart rhythms (arrythmias)<br />Peripheral neuropathies have been associated with fluoroquinolones use that symptoms may occur<br />soon after initiation of therapy and may be irreversible. If symptoms of peripheral neuropathy including<br />pain, burning, tingling, numbness and/or weakness develop, patients should immediately discontinue<br />fluoroquinolones and contact your physician.<br />if you have been diagnosed with leaking heart valves (heart valve regurgitation).<br />Have been diagnosed with an enlargement or &ldquo;bulge&rdquo; of a large blood vessel (aortic aneurysm or large<br />vessel peripheral aneurysm ).<br />Have experienced a previous episode of aortic dissection (a tear in the aorta wall).<br />if you are diabetic because you may experience a risk of hypoglycaemia with ciprofloxacin.<br />if you or a member of your family is known to have a deficiency in glucose-6-phosphate dehydrogenase<br />(G6PD), since you may experience a risk of anaemia with ciprofloxacin.<br />Have a family history of aortic aneurysm or aortic dissection or other risk factors or predisposing<br />conditions (e.g. connective tissue disorders such as Marfan syndrome, or vascular Ehlers-Danlos<br />syndrome, or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet&rsquo;s disease, high<br />blood pressure, or known atherosclerosis).<br />Feel sudden, severe pain in your abdomen, chest or back, go immediately to an emergency room.<br />Be aware that the symptoms of aortic aortic aneurysm do not often appear until the mother becomes<br />a large blood or bursts, so report any unusual side effects of taking fluoroquinolones to your healthcare<br />professional immediately.<br />For the treatment of some genital tract infections, your doctor can prescribe another antibiotic in<br />addition to ciprofloxacin. If there is no improvement in symptoms after 3 days of treatment, please<br />consult your doctor.<br /><strong>While taking FLOXACIN</strong><br />Tell your doctor immediately, if any of the following occurs while taking FLOXACIN. Your doctor will<br />decide whether treatment with FLOXACIN needs to be stopped.<br />Severe, sudden allergic reaction (an anaphylactic reaction/shock, angio-oedema). Even with the first<br />dose, there is a small chance that you may experience a severe allergic reaction with the following<br />symptoms: tightness in the chest, feeling dizzy, sick or faint, or experiencing dizziness when standing up.<br />If this happens, stop taking FLOXACIN and contact your doctor immediately.<br />Pain and swelling in the joints and tendinitis may occur occasionally, particularly if you are elderly and<br />are also being treated with corticosteroids. At the first sign of any pain or inflammation stop taking<br />FLOXACIN and rest the painful area. Avoid any unnecessary exercise, as this might increase the risk of<br />a tendon rupture.<br />If you suffer from epilepsy or other neurological conditions such as cerebral ischemia or stroke, you<br />may experience side effects associated with the central nervous system. If this happens, stop taking<br />FLOXACIN and contact your doctor immediately.<br />You may experience psychiatric reactions the first time you take FLOXACIN. If you suffer from depression<br />or psychosis, your symptoms may become worse under treatment with FLOXACIN. If this happens, stop<br />taking FLOXACIN and contact your doctor immediately.<br />You may experience symptoms of neuropathy such as pain, burning, tingling, numbness and/or<br />weakness. If this happens, stop taking FLOXACIN and contact your doctor immediately.<br />Diarrhoea may develop while you are taking antibiotics, including FLOXACIN, or even several weeks<br />after you have stopped taking them. If it becomes severe or persistent or you notice that your stool<br />contains blood or mucus, stop taking FLOXACIN immediately, as this can be life-threatening. Do not take<br />medicines that stop or slow down bowel movements and contact your doctor.<br />Tell the doctor or laboratory staff that you are taking FLOXACIN if you have to provide a blood or urine<br />sample.<br />FLOXACIN may cause liver damage. If you notice any symptoms such as loss of appetite, jaundice<br />(yellowing of the skin), dark urine, itching, or tenderness of the stomach, stop taking FLOXACIN and<br />contact your doctor immediately.<br />FLOXACIN may cause a reduction in the number of white blood cells and your resistance to infection may<br />be decreased. If you experience an infection with symptoms such as fever and serious deterioration of<br />your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or<br />urinary problems you should see your doctor immediately. A blood test will be taken to check possible<br />reduction of white blood cells (agranulocytosis). It is important to inform your doctor about your<br />medicine.<br />Tell your doctor if you or a member of your family is known to have a deficiency in glucose-6-phosphate<br />dehydrogenase (G6PD), since you may experience a risk of anemia with ciprofloxacin.<br />Your skin becomes more sensitive to sunlight or ultraviolet (UV) light when taking FLOXACIN. Avoid<br />exposure to strong sunlight, or artificial UV light such as sunbeds.<br />Quinolone antibiotics may cause an increase of your blood sugar levels above normal levels<br />(hyperglycaemia), or lowering of your blood sugar levels below normal levels, potentially leading to loss<br />of consciousness (hypoglycaemic coma) in severe cases (see section 5). This is important for people who<br />have diabetes. If you suffer from diabetes, your blood sugar should be carefully monitored.<br />If your eyesight becomes impaired or if your eyes seem to be otherwise affected, consult an eye<br />specialist immediately.<br />You may experience symptoms of neuropathy such as pain, burning, tingling, numbness and/or<br />weakness (Which might be irreversible). If this happens, inform your doctor immediately prior to<br />continuing treatment with Floxacin.<br />You may experience mental health problems even when taking quinolone antibiotics, including Floxacin,<br />for the first time. In very rare cases depression or mental health problems have led to suicidal thoughts<br />and self-injurious behavior such as suicide attempts (see section 5. Possible side effects). If you develop<br />such reactions, stop taking Floxacin and inform your doctor immediately.<br /><strong>Taking other medicines</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines,<br />including any that you obtained without a prescription.<br /><strong>Do not take FLOXACIN together with tizanidine,</strong> because this may cause side effects such as low blood<br />pressure and sleepiness (see Section 3: &laquo;Do not take FLOXACIN&raquo;).<br />The following medicines are known to interact with FLOXACIN in your body. Taking FLOXACIN together<br />with these medicines can influence the therapeutic effect of those medicines. It can also increase the<br />probability of experiencing side effects.<br /><strong>Tell your doctor if you are taking:</strong><br />Warfarin or other oral anti-coagulants (to thin the blood)<br />Probenecid (for gout)<br />Methotrexate (for certain types of cancer, psoriasis, rheumatoid arthritis)<br />Theophylline (for breathing problems)<br />Tizanidine (for muscle spasticity in multiple sclerosis)<br />Clozapine (an antipsychotic)<br />Olanzapine (an antipsychotic)<br />Metoclopramide (for nausea and vomiting)<br />Cyclosporin (for skin conditions, rheumatoid arthritis and in organ transplantation)<br />Other medicines that can alter your heart rhythm: medicines that belong to the group of antiarrhythmics<br />(e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide), tricyclic<br />antidepressants, some antimicrobials (that belong to the group of macrolides), some antipsychotics.<br />Zolpidem (for sleep disorders)<br />Ropinirole (for parkinson&rsquo;s disease)<br />Phenytoin (for epilepsy)<br />FLOXACIN may increase the levels of the following medicines in your blood:<br />Pentoxifylline (for circulatory disorders)<br />Caffeine<br />Duloxetine (for depression, diabetic nerve damage or incontinence)<br />Lidocaine (for heart conditions or anaesthetic use)<br />Sildenafil (e.g. for erectile dysfunction)<br />Agomelatine (for depression)<br />Some medicines reduce the effect of floxacin. Tell your doctor if you take or wish to take:<br />Antacids<br />Mineral supplements<br />Omeprazole<br />Sucralfate<br />A polymeric phosphate binder (e.g. Sevelamer or lanthanum carbonate)<br />Medicines or supplements containing calcium, magnesium, aluminium or iron<br />If these preparations are essential, take FLOXACIN about two hours before or no sooner than four hours<br />after them.<br /><strong>Taking FLOXACIN with food and drink</strong><br />Unless you take FLOXACIN during meals, do not eat or drink any dairy products (such as milk or yoghurt)<br />or drinks with added calcium when you take the tablets, as they may affect the absorption of the active<br />substance.<br /><strong>Pregnancy and breast-feeding</strong><br />It is preferable to avoid the use of FLOXACIN during pregnancy. Tell your doctor if you are planning to<br />get pregnant.<br />Do not take FLOXACIN during breast feeding because ciprofloxacin is excreted in breast milk and can be<br />harmful for your child.<br /><strong>Driving and using machines</strong><br />FLOXACIN may make you feel less alert. Some neurological adverse events can occur. Therefore, make<br />sure you know how you react to FLOXACIN before driving a vehicle or operating machinery. If in doubt,<br />talk to your doctor.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take FLOXACIN exactly as your doctor has told you. You should check with your doctor or<br />pharmacist if you are not sure.<br />Your doctor will explain to you exactly how much FLOXACIN you will have to take as well as how often<br />and for how long. This will depend on the type of infection you have and how bad it is. It is important<br />that you complete the course of treatment as directed by your doctor even if you feel better.<br />Tell your doctor if you suffer from kidney problems because your dose may need to be adjusted.<br />The treatment usually lasts from 5 to 21 days, but may take longer for severe infections. Take the tablets<br />exactly as your doctor has told you. Ask your doctor or pharmacist if you are not sure how many tablets<br />to take and how to take FLOXACIN.<br /><strong>Adults</strong><br />The dose to be taken will depend on the type of infection to be treated and how severe it is. The usual<br />dose ranges from a single dose of 250mg to between 250mg and 750mg of FLOXACIN twice daily.<br />Treatment is usually for 5-10 days or for at least 3 days after the signs of infection have gone. The<br />following doses may be given for specific infections:<br /><strong>Chest infections (bronchitis, pneumonia)</strong><br />The usual dose is 500 &ndash; 750mg of FLOXACIN twice daily. Treatment for a chest infection is usually for<br />7 &ndash; 14 days. The usual dose to treat a chest infection in a cystic fibrosis patient is 750 mg of FLOXACIN<br />twice daily.<br /><strong>Urinary tract infections</strong><br />To treat cystitis a dose of 250 mg of FLOXACIN twice daily may be given. For more severe infections, the<br />dose may range from 250 mg to 500 mg twice daily.<br /><strong>Gonorrhoea </strong>&ndash; A single dose of 500 mg of FLOXACIN may be given.<br /><strong>Anthrax </strong>&ndash; The usual dose is 500mg twice a day. Treatment should continue for 2 months.<br /><strong>Elderly</strong><br />The dose will depend on your kidney function and how severe your infection is. Your doctor will give you<br />the lowest possible dose to treat your infection.<br /><strong>Children and adolescents</strong><br />FLOXACIN is not usually given to children except in specific cases:<br /><strong>To treat cystic fibrosis patients (5 &ndash; 17 years) with a chest infection</strong> &ndash; 20mg per kg of body weight twice<br />a day may be given for 10-14 days. The maximum dose is 1500mg a day.<br /><strong>Urinary tract or kidney infections</strong> &ndash; 10mg to 20mg per kg of body weight twice daily. The maximum dose<br />is 750mg twice daily. Treatment may be given for 10 days or up to three weeks.<br /><strong>Anthrax </strong>&ndash; 10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of<br />500 mg per dose, 60 days.<br />Some patients may need regular blood tests to check the level of FLOXACIN in their blood.<br />Swallow the tablets with plenty of fluid. Do not chew the tablets because they do not taste nice.<br />Do try to take the tablets at around the same time every day.<br />You can take the tablets at mealtimes or between meals. Any calcium you take as part of a meal will<br />not seriously affect uptake. However, do not take FLOXACIN tablets with dairy products such as milk or<br />yoghurt or with fortified fruit juices (e.g. calcium-fortified orange juice).<br /><strong>If you take more FLOXACIN than you should</strong><br />If you take more than the prescribed dose, get medical help immediately. If possible, take your tablets<br />or the box with you to show the doctor.<br /><strong>If you forget to take FLOXACIN</strong><br />Take the normal dose as soon as possible and then continue as prescribed. However, if it is almost time<br />for your next dose, do not take the missed dose and continue as usual. Do not take a double dose to<br />make up for a forgotten dose. Be sure to complete your course of treatment.<br /><strong>If you stop taking FLOXACIN</strong><br />It is important that you finish the course of treatment even if you begin to feel better after a few days. If<br />you stop taking this medicine too soon, your infection may not be completely cured and the symptoms<br />of the infection may return or get worse. You might also develop resistance to the antibiotic.<br />If you have any more questions about the use of this product, ask your doctor or pharmacist.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, FLOXACIN can cause side effects, although not everybody gets them.<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell your<br />doctor or pharmacist.<br /><strong>&bull; Common (may affect up to 1 in 10 people):</strong><br />Nausea, diarrhoea.<br />Joint pains and joint inflammation in children.<br /><strong>&bull; Uncommon (may affect up to 1 in 100 people):</strong><br />Fungal superinfections.<br />A high concentration of eosinophils, a type of white blood cell.<br />Loss of appetite (anorexia).<br />Hyperactivity or agitation.<br />Headache, dizziness, sleeping problems, or taste disorders.<br />Vomiting, abdominal pain, digestive problems such as stomach upset (indigestion/heartburn), or wind.<br />Increased amounts of certain substances in the blood (transaminases and/or bilirubin).<br />Rash, itching, or hives.<br />Joint pain in adults.<br />Poor kidney function.<br />Pains in your muscles and bones, feeling unwell (asthenia), or fever.<br />Increase in blood alkaline phosphatase (a certain substance in the blood).<br /><strong>&bull; Rare (may affect up to 1 in 1,000 people):</strong><br />Inflammation of the bowel (colitis) linked to antibiotic use (can be fatal in very rare cases) (see Section<br />3: Take special care with FLOXACIN).<br />Changes to the blood count (leukopenia, leukocytosis, neutropenia, anaemia), increased or decreased<br />amounts of a blood clotting factor (thrombocytes).<br />Allergic reaction, swelling (oedema), or rapid swelling of the skin and mucous membranes (angiooedema).<br />Increased blood sugar (hyperglycaemia).<br />Lowering of blood glucose levels (hypoglycemia) lowering of blood glucose levels, signs of hypoglycemia<br />include, confusion, pounding heart or very fast pulse, dizziness, pale skin, feeling shaky, sweating,<br />unusual hunger, trembling, headaches, weakness, irritability and unusual anxiety.<br />Confusion, disorientation, anxiety reactions, strange dreams, depression, or hallucinations.<br />Pins and needles, unusual sensitivity to stimuli of the senses, decreased skin sensitivity, tremors,<br />seizures (see Section 3: Take special care with FLOXACIN), or giddiness. Hypoglycemia can lead to coma.<br />Disturbances in attention, nervousness, and serious disturbances in mental abilities called delirium.<br />Eyesight problems.<br />Tinnitus, loss of hearing, impaired hearing.<br />Rapid heartbeat (tachycardia).<br />Expansion of blood vessels (vasodilation), low blood pressure, or fainting.<br />Shortness of breath, including asthmatic symptoms.<br />Liver disorders, jaundice (cholestatic icterus), or hepatitis.<br />Sensitivity to light (see Section 3: Take special care with FLOXACIN).<br />Muscle pain, inflammation of the joints, increased muscle tone, or cramp.<br />Kidney failure, blood or crystals in the urine (see Section 3: Take special care with FLOXACIN), urinary<br />tract inflammation.<br />Fluid retention or excessive sweating.<br />Abnormal levels of a clotting factor (prothrombin) or increased levels of the enzyme amylase.<br /><strong>&bull; Very rare (may affect up to 1 in 10,000 people):</strong><br />A special type of reduced red blood cell count (haemolytic anaemia); a dangerous drop in a type of<br />white blood cells (agranulocytosis ); a drop in the number of red and white blood cells and platelets<br />(pancytopenia), which may be fatal; and bone marrow depression, which may also be fatal (see Section<br />3: Take special care with FLOXACIN).<br />Severe allergic reactions (anaphylactic reaction or anaphylactic shock, which can be fatal - serum<br />sickness) (see Section 3: Take special care with FLOXACIN).<br />Mental disturbances (psychotic reactions) (see Section 3 Take special care with FLOXACIN).<br />Migraine, disturbed coordination, unsteady walk (gait disturbance), disorder of sense of smell (olfactory<br />disorders), pressure on the brain (intracranial pressure).<br />Visual color distortions.<br />Inflammation of the wall of the blood vessels (vasculitis).<br />Pancreatitis.<br />Death of liver cells (liver necrosis) very rarely leading to life-threatening liver failure.<br />Small, pin-point bleeding under the skin (petechiae); various skin eruptions or rashes (for example, the<br />potentially fatal Stevens-Johnson syndrome or toxic epidermal necrolysis).<br />Worsening of the symptoms of myasthenia gravis (see Section 3: Take special care with FLOXACIN).<br /><strong>&bull; Not known (frequency cannot be estimated from the available data)</strong><br />Abnormal fast heart rhythm, life-threatening irregular heart rhythm, alteration of the heart rhythm<br />(called &ldquo;prolongation of QT interval&rdquo;, seen on ECG, electrical activity of the heart)<br />- influence on blood clotting (in patients treated with Vitamin K antagonists)<br />- Feeling highly excited (mania) or feeling great optimism and overactivity (hypomania).<br />- Syndrome associated with impaired water excretion and low levels of sodium (SIADH)<br />- Loss of consciousness due to severe decreas<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Store below 30&deg;C.<br />Do not use FLOXACIN after the expiry date which is stated on the carton. The expiry date refers to the<br />last day of that month.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to<br />dispose of medicines no longer required. These measures will help to protect the environment<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-The active substance is ciprofloxacin.<br />Each film-coated tablet contains ciprofloxacin (as hydrochloride). Equivalent to 500 mg of the active<br />substance ciprofloxacin<br />-The other ingredients are:<br />Avicel (PH102), Corn Starch, Croscarmellose sodium, Polysorbate )80(, Povidone (K30), Sodium Starch<br />Glycolate, Talc, Aerosil, Mg stearate, Opadry white.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                FLOXACIN 500 mg tablets: Round white to creamy biconvex film coated tablet. Coded by (SJ125) in one
side. In Packs of: 10 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals<br />Saudi Arabian Japanese pharmaceutical company limited<br />Jeddah &ndash; Saudi Arabia<br /><strong>For any information about FLOXACIN, please contact</strong><br />Saudi Arabian Japanese pharmaceutical company limited<br />Jeddah &ndash; Saudi Arabia<br />P.O. Box: 42600, Jeddah 21551, KSA<br />Tel: + 966 12 606 6667<br />sajapharma.com<br />This leaflet was last revised in {April/2023}; version number {00}<br /><strong>-To report any side effect(s):</strong><br /><strong>&bull; Saudi Arabia</strong><br />&bull; The National Pharmacovigilance Centre (NPC):<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/<br /><strong>&bull; Other GCC states /other countries</strong><br />-Please contact the relevant competent authority.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>فلوكساسـين هـو مضـاد حيـوي ينتمـي لعائلـة الــ &laquo;فلوروكينولونـات.&raquo; المـادة الفعالـة هـي سيبروفلوكساسـين. سيبروفلوكساسـين يعمل من<br />خلال القضـاء عـى البكتيريـا التـي تسـبب العـدوى. وهـو فعال فقـط تجاه سلالات معينـة مـن البكتيريا.<br /><strong>البالغون</strong><br />يُستخدم فلوكساسين في البالغين لعلاج العدوى البكتيرية التالية:<br />عدوى الجهاز التنفسي.<br />عدوى الأذن أو الجيوب الأنفية طويلة الأمد أو المتكررة.<br />عدوى الجهاز البولي.<br />عدوى الخصيتين.<br />عدوى أعضاء الجهاز التناسلي لدى النساء.<br />عدوى الجهاز الهضمي، والعدوى داخل البطن.<br />عدوى الجلد والأنسجة الرخوة.<br />عدوى العظام والمفاصل.<br />لعلاج العدوى في المرضى الذين يعانون من انخفاض شديد في عدد خلايا الدم البيضاء.<br />لتجنب العدوى في المرضى الذين يعانون من انخفاض شديد في عدد خلايا الدم البيضاء (قلَّة َ العدلات.)<br />لمنع العدوى الناتجة عن بكتيريا النيسيرية السحائية.<br />التعرض لاستنشاق الجمرة الخبيثة.<br />إذا كنـت تعـاني مـن عـدوى شـديدة أو تلـك الناتجـة عـن أكـثًر من نـوع واحد مـن البكتيريا، فقـد يتم إعطـاؤك مضـادا حيويًّا آخـر للعلاج<br />بالإضافة إلى فلوكساسـين.<br /><strong>الأطفال والمراهقون:</strong><br />يستخدم فلوكساسين في الأطفال والمراهقين، تحت إشراف طبي متخصص، لعلاج العدوى البكتيرية التالية:<br />عدوى بالرئة والشعب الهوائية لدى الأطفال والمراهقين الذين يعانون من التليف الكيسي.<br />مضاعفات عدوى الجهاز البولي، بما في ذلك العدوى التي امتدت إلى الكلى (التهاب الحويضة والكلية.)<br />التعرض لاستنشاق الجمرة الخبيثة.<br />ً يمكن أيضا استخدام فلوكساسين لعلاج عدوى أخرى شديدة ومعينة لدى الأطفال والمراهقين، إذا رأى طبيبك أن ذلك أمر ٌّ ضروري.<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا يستخدم فلوكساسين في الحالات التالية:</strong><br />ٍّ اذا كنـت تعـاني مـن الحساسـية (فـرط الحساسـية) تجـاه المـادة الفعالـة، تجـاه أدويـة الــ &laquo;كينولـون&raquo; الأخـرى أو تجـاه أي مـن المكونـات<br />الأخـرى بــ&raquo; فلوكساسـين&raquo; (انظـر القسـم )7<br />اذا كنت تتناول دواء تيزانيدين (انظر القسم &laquo; :3تناول أدوية أخرى.)&raquo;<br />اذا كنت تعاني من الصرع<br />لعلاج الالتهابات التي قد تتحسن دون علاج أو ليست شديدة (مثل التهابات الحنجرة)<br />لعلاج العدوى الغير بكتيرية, مثال: التهاب البروستات الغير بكتيري<br />للوقاية من إسهال المسافر أو التهابات المسالك البولية السفليه المتكررة (عدوى البول التي لا تمتد إلى ما بعد المثانة)<br />لعلاج الالتهابات البكتيرية الخفيفة أو المتوسطه ما لم يكن من الممكن استخدام أدوية مضادة للبكتيريا أخرى موصى بها لهذه العدوى<br />الأهـم مـن ذلـك ، يجـب تجنـب الفلوروكينولونـات بشـكل عـام في المـرضى الذين لديهـم آثار جانبيـة خطيرة مـن قبل مع مضـادات حيوية<br />الفلوروكوينولـون أو الكينولون<br /><strong>ً توخ حذرا خاصا مع فلوكساسين</strong><br /><strong>قبل تناول فلوكساسين</strong><br />تحدث إلى طبيبك قبل تناول فلوكساسين<br />أخبر الطبيب الخاص بك إذا كنت:<br />ُ قد عانيت من قبل من مشاكل في الكلى حيث إن علاجك قد يحتاج إلى التعديل.<br />ِ تعاني من مرض الصرع أو غيره من الحالات العصبية.<br />لديك تاريخ مرضي لحدوث مشاكل بالأوتار أثناء علاج سابق بالمضادات الحيوية مثل فلوكساسين.<br />يجـب اسـتخدامه بحـذر خـاص عنـد كبـار السـن ، والمـرضى الذين يعانـون من أمـراض الكلى وأولئـك الذين أجريـت لهم عمليـة زرع عضو<br />لأن هـؤلاء المـرضى يكونون أكـر عرضة للإصابـة بالأوتار.<br />ً بما أن استخدام الكورتيكوستيرويدات مع الفلوروكينولون يزيد أيضا من هذا الخطر ، فيجب تجنب الاستخدام المشترك لهذه الأدوية.<br />تعاني من الوهن العضلي الوبيل (وهو نوع من ضعف العضلات.)<br />لديك تاريخ مرضي من عدم انتظام ضربات القلب (اضطرابات النظم القلبي.)<br />اعتـلال الأعصـاب الطرفيـة : قـد تظهـر اعـراض اعتـلال الأعصـاب الطرفيـة بعـد بدء اسـتعمال فلوكساسـين ويمكـن أن تكون هـذه الاعراض<br />دائمـة. عنـد حـدوث أعـراض الاعتـلال العصبـي بمـا في ذلك الاحسـاس بـالألم، الحرقـان، الوخز، الخـدر و / أو الضعـف ، ينبغـي التوقف فورا<br />عـن اسـتعمال فلوكساسـين والاتصال بالطبيـب المعالج.<br />إذا تم تشخيصك بتسرب صمامات القلب (قلس صمام القلب.)<br />ً إذا لم تكن متأكدا مما إذا كان ينطبق عليك أيًّا مما سبق، فيرجى التحدث إلى طبيبك أو الصيدلى قبل تناول فلوكساسين.<br />قد تم تشخيصك بتوسع أو &laquo;انتفاخ&raquo; في وعاء دموي كبير (أم الدم الأبهرية أو تمدد الأوعية الدموية المحيطية الكبيرة.)<br />قد تعرضت سابقا لتمزق في جدار الأبهر.<br />لديك تاريخ عائلي من تمدد الأوعية الدموية الأبهري أو تَسلُّخ الأبهر أو عوامل الخطر الأخرى أو شروط الاستعداد.<br />إذا كنت مصابًا بمرض السكري لأنك قد تواجه خطر الإصابة بنقص سكر الدم مع استخدام سيبروفلوكساسين<br />إذا كان مـن المعـروف أنـك أو أحـد أفـراد أسرتـك مصـاب بعـوز نازعـة هيدروجـين الغلوكوز--6فوسـفات ، حيـث يمكن ان تعـاني من خطر<br />الإصابـة بفقر الـدم مع سيبروفلوكساسـين.<br />إضطرابـات النسـيج الضـام مثـل متلازمـة مارفـان ، أو متلازمـة الألفـرس داهلـوس ، أو اضطرابـات الأوعيـة الدمويـة مثـل التهـاب الشرايين<br />تاكاياسـو ، إلتهـاب الشريـان الخلـوي، أو &laquo;داء&raquo; بيشـيت، أو ارتفـاع ضغـط الـدم، أو تصلـب الشرايـين المعـروف.<br />شعرت بألم مفاجئ وشديد في البطن والصدر أو الظهر ، اذهب عى الفور إلى الطوارئ.<br />يجـب ملاحظـة أن أعـراض تمـدد الأوعيـة الدمويـة الأبهـري لا تظهـر غالبًـا حتـى يصبـح التمـدد كبـيرا أو ينفجـر ، لذلـك أبلـغ عـن أي آثار<br />جانبيـة غـير عاديـة لأخـذ الفلوروكينولونـات إلى أخصـائي الرعايـة الصحيـة عـلى الفور.<br />لعلاج بعـض التهابـات الجهـاز التناسـلي ً ، يمكـن لطبيبـك أن يصـف لـك مضـادا حيويًـا آخـر بالإضافـة إلى سيبروفلوكساسـين. إذا لم تتحسـن<br />الأعـراض بعـد 3 أيـام مـن العلاج ، برجـاء اسـتشر طبيبك.<br /><strong>أثناء تناول فلوكساسين</strong><br />ً أخبر طبيبك فورا، إذا ظهر أي من التالي أثناء تناول فلوكساسين. سيقرر طبيبك ما إذا كانت هناك حاجة لوقف العلاج .<br />حـدوث مفاجـئ لتفاعـل حساسـية شـديد (تفاعـل تأقي/ صدمـة، وذمة وعائية.) حتـى مع الجرعـة الأولى، هناك فرصة ضئيلـة لتعرضك إلى<br />تفاعـل حساسـية شـديد مـع الأعـراض التاليـة: ضيـق في الصدر، والشـعور بدوخة أو إعيـاء أو إغماء، أو تعـاني من الدوخة عنـد الوقوف. إذا<br />حـدث ذلـك، توقف عـن تناول فلوكساسـين ً واتصل بطبيبـك فورا.<br />قـد يحـدث أحيانًـا ألم وتـورم في المفاصـل والأوتـار، خاصـة إذا كنـت من المسـنين، ويتم علاجـك بالـ &laquo;كورتيكوسـتيرويدات.&raquo; عنـد أول علامة<br />لحـدوث أي ألم أو التهـاب، توقـف عـن تنـاول فلوكساسـين ِ وأرح المنطقـة المؤلمـة. تجنـب ممارسـة أي نشـاط لا داع لـه؛ لأن ذلـك قـد يزيد<br />مـن خطر حـدوث تمـزق بالأوتار.<br />إذا كنـت تعـاني مـن مـرض الـصرع أو غـيره مـن الحـالات العصبيـة مثـل نقص الترويـة الدماغـي أو السـكتة الدماغيـة، قد تتعـرض لأعراضاً<br />جانبيـة مرتبطـة بالجهـاز العصبـي المركـزي. إذا حـدث ذلـك، توقـف عن تنـاول فلوكساسـين ً واتصل بطبيبـك فورا.<br />قـد تتعـرض لـردود فعـل نفسـية عنـد تناولـك فلوكساسـين للمـرة الأولى. إذا كنـت تعـاني مـن اكتئـاب أو ذهـان، فقـد تسـوء الأعـراض مـع<br />العلاج بــ &laquo;فلوكساسـين.&raquo; إذا حـدث ذلـك، توقـف عـن تنـاول فلوكساسـين ً واتصـل بطبيبـك فورا.<br />قـد تتعـرض إلى أعـراض الاعتـلال العصبـي مثل الشـعور بـألم، حرقة، وخز، خـدر و/أو ضعف. إذا حـدث ذلك، توقف عن تناول فلوكساسـين<br />ً واتصـل بطبيبك فورا.<br />قـد تعـاني مـن الإسـهال أثنـاء تناولـك لمضـادات حيوية، بمـا في ذلك فلوكساسـين، أو حتى أسـابيع عديدة بعد توقفـك عن تناولهـا. إذا أصبح<br />ً الإسـهال شـديد ً ا أو مسـتمرا أو لاحظـت أن الـبراز يحتـوي عـى دم أو مخـاط، توقـف عن تناول فلوكساسـين ً فـورا، حيث يمكن لهـذه الحالة<br />أن تكـون مهـددة للحيـاة. لا تتنـاول الأدويـة التي توقـف أو تبطئ مـن حركة الأمعاء واتصـل بطبيبك.<br />أخبر الطبيب أو موظف المختبر أنك تتناول فلوكساسين إذا كان يجب عليك تقديم عينة دم أو بول.<br />قـد يتسـبب فلوكساسـين في تلـف الكبـد. إذا لاحظـت أية أعـراض مثل: فقدان الشـهية، واليرقـان (اصفرار الجلـد،) والبول الداكـن، والحكة،<br />أو ألم بالمعـدة، فتوقـف عـن تناول فلوكساسـين ً واتصـل بطبيبك فورا.<br />قـد يتسـبب فلوكساسـين في خفـض عـدد خلايـا الـدم البيضـاء، وقـد تقل مقاومتـك للعـدوى. إذا كنـت تعاني من عـدوى مع ظهـور أعراض<br />مثـل حمـى وتدهـور خطـير لحالتـك العامـة، أو حمـى مـع أعـراض عـدوى موضعيـة، مثـل مشـاكل في: التهـاب الحلـق/ البلعـوم/ الفم، أو<br />ً في الجهـاز البـولي، فيجـب مراجعـة طبيبـك فـورا. وسـيتم إجـراء فحـص دم للتحقق مـن احتمالية انخفـاض عدد خلايـا الدم البيضـاء (ندرة<br />المحببـات.) مـن الهـام إخبـار طبيبـك عن الأدويـة التـي تتناولها.<br />أخـبر طبيبـك إذا علمـت أنـك أو أحـد أفـراد عائلتك تعـاني من نقـص أنزيم نازعـة هيدروجـين الجلوكوز--6فوسـفات (أنيميا الفـول)؛ لأنك<br />قـد تواجـه خطر الإصابـة بفقر الـدم مع سيبروفلوكساسـين.<br />قـد تسـبب المضـادات الحيويـة الكينولـون زيـادة في مسـتويات السـكر في الدم فـوق المسـتويات الطبيعية (فرط سـكر الـدم) ، أو انخفاض<br />مسـتويات السـكر في الـدم عـن المسـتويات الطبيعيـة ، مـما قـد يـؤدي إلى فقدان الوعـي (غيبوبة سـكر الـدم) في الحالات الشـديدة (انظر<br />القسـم .)5هـذا مهـم للأشـخاص المصابـين بـداء السـكري. إذا كنـت تعـاني من مرض السـكري ، يجب مراقبة نسـبة السـكر في الـدم بعناية.<br />إذا ضعف بصرك أو إذا بدت عيناك متأثرة بطريقة أخرى ، فاستشر طبيب عيون على الفور.<br />يُصبـح جلـدك أكـر حساسـية لضـوء الشـمس أو الضـوء فـوق البنفسـجي UVعنـد تنـاول فلوكساسـين. تجنـب التعـرض لضوء الشـمس<br />الشـديد، أو الأضـواء فـوق البنفسـجية الاصطناعيـة مثـل الغـرف الشمسـية الاصطناعية.<br />قـد تُعـاني مـن أعـراض الاعتـلال العصبـي مثـل الشـعور بـألم، حرقـة، وخـز، تنميـل و/ أو ضعـف (قد تكـون دائمـه.) إذا حدث ذلـك فُيرجى<br />إبـلاغ طبيبـك عـى الفور قبـل الاسـتمرار في العلاج بفلوكساسـين.<br />قـد تُعـاني مـن اضطرابـات نفسـية، حتـى عنـد تنـاول المضـادات الحيويـة مـن فئـة الكينولـون، بمـا فيهـا فلوكساسـين، لأول مـرة. في حالات<br />ًّ نـادرة جـدا، أدت الإصابـة بالاكتئـاب أو الاضطرابـات النفسـية إلى أفـكار انتحاريـة وسـلوك مـضر بالنفـس مثـل محـاولات الانتحـار (انظـر<br />قسـم &laquo; 5الاعـراض الجانبيـة المُحتملـة.)&raquo; إذا تعرضـت لهـذه الاعـراض، فتوقـف عـن تنـاول فلوكساسـين، ويُرجـى إبـاغ طبيبك عـى الفور.<br /><strong>تناول أدوية أخرى</strong><br />يُرجـى إبلاغ الطبيـب أو الصيـدلي الخـاص بـك، إذا كنـت تتنـاول أو تناولـت مؤخـرا أيـة أدويـة أخـرى، بمـا في ذلـك الأدويـة التـي حصلـت<br />عليهـا دون وصفـة طبيـة.<br />لا تتنـاول فلوكساسـين مـع تيزانيديـن؛ وذلـك لأن هـذا قـد يسـبب أعراضـاً جانبيـة مثـل انخفاض ضغـط الدم ونُعـاس (انظر القسـم &laquo; :3لا<br />تتناول فلوكساسـين.)&raquo;<br />مـن المعـروف أن الأدويـة التاليـة تتفاعل مع فلوكساسـين ُ في جسـمك. تناول فلوكساسـين مع هـذه الأدوية يؤثر عى المفعـول العلاجي لتلك<br />ً الأدويـة. ويمكـن أن تزيـد أيضا هذه الأدوية مـن احتمالية التعرض للأعـراض الجانبية.<br />أخبر طبيبك إذا كنت تتناول:<br />وارفارين أو غيره من مضادات التخثر التي يتم تناولها عن طريق الفم (لزيادة سيولة الدم.)<br />بروبينيسيد (لعلاج النقرس.)<br />ميثوتريكسيت (لعلاج أنواع معينة من السرطان، والصدفية، والتهاب المفاصل الروماتويدي.)<br />ثيوفيللين (لعلاج مشاكل التنفس.)<br />تيزانيدين (لعلاج تشنج العضلات في مرض التصلب المتعدد.)<br />كلوزابين (دواء مضاد للذهان.)<br />أولانزابين (مضاد للذهان)<br />ميتوكلوبراميد (للغثيان والقيء)<br />السيكلوسبورين (للأمراض الجلدية والتهاب المفاصل الروماتويدي وزرع الأعضاء)<br />الأدوية الأخرى التي يمكن أن تغير معدل ضربات قلبك: الأدوية التي تنتمي إلى مجموعة مضادات اضطراب النظم<br />ُ (مثـل كينيديـن ، هيدروكينيديـن ، ديسـوبيراميد ، أميـودارون ، سـوتالول ، دوفيتيليـد ، إيبوتيليـد) ، مضـادات ِ الاكْتئـاب الثُّلاثِيَّة َ الحلَقات ،<br />بعـض مضـادات الميكروبـات (التـي تنتمـي إلى مجموعـة الماكروليـدات) ، وبعض مضـادات الذهان.<br />الزولبيديم (لاضطرابات النوم.)<br />روبينيرول (لعلاج مرض باركنسون &laquo;الشلل الرعاش.)&raquo;<br />فينيتوين (لعلاج مرض الصرع.)<br />يمكن أن يزيد فلوكساسين من مستويات الأدوية التالية في الدم:<br />بنتوكسيفيللين (لعلاج اضطرابات الدورة الدموية.)<br />كافيين.<br />دولوكستين (للاكتئاب أو تلف الأعصاب السكري أو سلس البول)<br />ليدوكائين (لعلاج أمراض القلب أو الاستخدام للتخدير)<br />سيلدينافيل (على سبيل المثال لعلاج ضعف الانتصاب)<br />أغومياتين (للاكتئاب)<br />قد تقلل بعض الأدوية من تأثير فلوكساسين. أخبر طبيبك إذا كنت تتناول أو ترغب في تناول:<br />مضادات الحموضة.<br />مكملات غذائية تحتوي عى المعادن.<br />اوميبرازول.<br />سكرالفات.<br />لاقطات الفوسفات البوليمرية (عى سبيل المثال Sevelamerأو كربونات الانثانم.)<br />الأدوية أو المكملات الغذائية التي تحتوي عى كالسيوم وماغنسيوم وألومنيوم أو حديد،<br />إذا كانت هذه الاحتياطات ضرورية، تناول فلوكساسين نحو ساعتين قبل أو بعد ما لا يقل عن أربع ساعات من تناولهم.<br /><strong>تناول فلوكساسين مع الطعام والشراب</strong><br />عنـد تنـاول الأقـراص، لا تـأكل أو تـشرب أيًّـا مـن منتجـات الألبـان (مثـل الحليـب أو الزبـادي،) أو المشروبات التـي تحتوي على كالسـيوم؛<br />لأنهـا قـد تُؤثـر عـى امتصـاص المـادة الفعالـة، إلا إذا كنت تتنـاول فلوكساسـين خلال وجبـات الطعام.<br /><strong>الحمل والرضاعة الطبيعية</strong><br />من الأفضل تجنب استخدام فلوكساسين خلال فترة الحمل. أخبري طبيبك ِ إذا كنت تنوين الحمل.<br />لا تتناولي فلوكساسين أثناء الرضاعة؛ لأن سيبروفلوكساسين يُفرز في لبن الأم، ويمكن أن يكون ضارا لطفلك.<br /><strong>القيادة واستخدام الآلات</strong><br />قـد يجعلـك فلوكساسـين تشـعر بأنـك أقـل يقظة. يمكن حـدوث بعض الأعـراض الجانبيـة العصبية؛ ولذلـك، تأكد من أنك تعـرف كيف هي<br />اسـتجابتك لـ &laquo;فلوكساسـين&raquo; قبل قيادة السـيارة أو اسـتخدام الآلات. في حالة الشـك، تحدث إلى طبيبك.<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تنـاول دائمًـا فلوكساسـين بالضبـط كـما أخـبرك طبيبـك. إذا لم تكـن متأكدا مـن كيفية الاسـتعمال، يجب عليـك مراجعة الطبيـب أو الصيدلي<br />الخـاص بك.<br />سـوف يـشرح لـك طبيبـك بالضبـط الكميـة التي يجـب أن تتناولها من فلوكساسـين فضلآ عـن عدد مرات ومـدة التناول. هذا سـيعتمد على<br />نـوع العـدوى التـي تعـاني منهـا، ومدى شـدتها. من المهـم أن تكمل دورة العـلاج وفقا لتوجيهات طبيبك حتى إذا كنت تشـعر بتحسـن.<br />ُ أخبر طبيبك إذا كنت تعاني من مشاكل في الكلى؛ لأن جرعتك قد تحتاج إلى تعديل.<br />تسـتمر عـادة مـدة العلاج مـن ً 5-21 يومـا، ولكن قـد تسـتغرق وقتًا أطول في حـالات العدوى الشـديدة. تنـاول دائمًا الأقـراص بالضبط كما<br />أخـبرك طبيبـك. اسـأل الطبيـب أو الصيـدلي الخـاص بـك إذا كنـت غير متأكد من عـدد الأقراص التـي سـتتناولها، وكيفية تناول فلوكساسـين.<br /><strong>البالغون</strong>:<br />تعتمـد الجرعـة التـي يجـب تناولهـا عـى نـوع العدوى التي سـيتم علاجهـا ومدى شـدتها. تـتراوح الجرعة المعتـادة من جرعة مفـردة 250<br />ملـج إلى جرعـة تـتراوح بـين 250ملـج و 750ملـج مـن فلوكساسـين مرتـين يوميًّا. تسـتمر عادة مـدة العلاج مـن 5-10أيام أو عـى الأقل 3<br />أيـام بعـد اختفـاء علامـات العـدوى. يمكن إعطـاء الجرعـات التالية لعلاج حـالات معينة مـن العدوى:<br /><strong>عدوى بالصدر (التهاب القصبات الهوائية والالتهاب الرئوي.)</strong><br />الجرعـة المعتـادة هـي 500 - 750ملـج مـن فلوكساسـين مرتـين يوميًّـا. تكـون مـدة علاج العدوى بالصـدر عادة مـن ً 7 - 14يومـا. الجرعة<br />المعتـادة لعلاج العـدوى بالصـدر في مريـض التليـف الكيـي هـي 750 ملج من فلوكساسـين مرتـين يوميًّا.<br /><strong>عدوى الجهاز البولي</strong><br />لعلاج التهـاب المثانـة: قـد تُعطـى جرعـة مـن 250 ملج مـن فلوكساسـين مرتـين يوميًّـا. للعـدوى الأكر شـدة، قد تـتراوح الجرعـة بين 250<br />ملـج إلى 500 ملج مرتـين يوميًّا.<br /><strong>مرض السيلان </strong>- يمكن أن تُعطى جرعة مفردة من 500 ملج من فلوكساسين.<br /><strong>الجمرة الخبيثة </strong>- الجرعة المعتادة هي 500 ملج مرتين في اليوم. وينبغي أن يستمر العلاج لمدة شهرين.<br /><strong>المرضى من كبار السن:</strong><br />ستعتمد الجرعة عى وظائف الكى لديك، و شدة العدوى. سيقوم طبيبك بإعطائك أقل جرعة ممكنة لعلاج العدوى.<br /><strong>الأطفال والمراهقون:</strong><br />لا يُعطى فلوكساسين عادةً للأطفال إلا في حالات محددة:<br /><strong>لعـلاج مـرضى التليـف الكيـسي ( 5 - 17عامـا) مـع عـدوى بالصـدر</strong> - يمكـن إعطـاء 20 ملج /كلـج مـن وزن الجسـم، مرتـين في اليـوم لمدة<br />ً 10-14 يومـا. الجرعـة القصـوى هـي 1500 ملج في اليـوم.<br /><strong>عـدوى الجهـاز البـولي أو الـكلى</strong> - 10ملـج إلى 20 ملـج / كلـج من وزن الجسـم، مرتـين يوميا. الجرعة القصـوى هي 750 ملج مرتـين يوميًّا.<br />يمكـن إعطـاء العلاج لمدة 10 أيـام أو حتى ثلاثة أسـابيع.<br /><strong>الجمـرة الخبيثـة</strong> - يمكـن إعطـاء 10ملـج / كجـم مـن وزن الجسـم مرتـين في اليـوم حتـى 15 ملج / كجم من وزن الجسـم مرتـين في اليوم<br />بحـد أقـى 500 ملج لـكل جرعـة ً 60يوما.<br />قد يحتاج بعض المرضى إلى إجراء اختبارات دم بصورة منتظمة للتحقق من مستوى &laquo;فلوكساسين&raquo; في الدم.<br />ابتلع الأقراص مع كمية كبيرة من السوائل. لا تمضغ الأقراص؛ حيث أن لها طعم غير مستساغ.<br />تناول الأقراص في نفس الوقت تقريبًا من كل يوم.<br />يمكنـك تنـاول الأقـراص أثنـاء تنـاول الطعـام أو بـين الوجبات. لا يُؤثـر الكالسـيوم الذي تتناولـه (كجزء من وجبـة الطعام) تأثـيرا خطيرا على<br />الامتصـاص. ومـع ذلـك، لا تتنـاول أقراص فلوكساسـين مع منتجات الألبـان مثل الحليب أو الزبـادي أو مع عصائر الفاكهـة الغنية بالإضافات<br />(مثـل عصير البرتقال الغني بالكالسـيوم.)<br />إ<strong>ذا تناولت كمية من فلوكساسين أكثر مما يجب:</strong><br />إذا تناولـت كميـة أكـبر ً مـن الجرعـة الموصوفـة لـك، فاطلب المسـاعدة الطبيـة فورا. إذا أمكـن ذلك ، خذ الأقـراص أو العبـوة معك لعرضهم<br />عـى الطبيب.<br /><strong>إذا نسيت تناول فلوكساسين:</strong><br />تنـاول الجرعـة المنسـية في أقـرب وقـت ممكـن ثـم تابـع علاجـك كالمعتـاد كـما وصـف لـك الطبيـب. ومـع ذلـك، إذا كان قـد حـان وقـت<br />الجرعـة التاليـة، فـلا تتنـاول الجرعـة المنسـية، واسـتمر كالمعتـاد. لا تتنـاول جرعـة مضاعفـة لتعويـض الجرعـة التـي نسـيتها. تأكـد مـن<br />اسـتكمالك لـدورة العلاج.<br /><strong>إذا توقفت عن تناول فلوكساسين:</strong><br />مـن المهـم أن تنهـي دورة العلاج حتـى إذا بـدأت تشـعر بتحسـن بعـد أيـام قليلـة. إذا توقفـت عـن تنـاول هـذا الـدواء في وقـت مبكـر<br />ًّ جـدا، قـد لا يتـم شـفاء العـدوى تمامـا لديـك، وقـد تعـاود أعراض العـدوى في الظهـور أو تزداد سـوءا. يمكـن أيضا أن تتطور لديـك مقاومة<br />للمضـاد الحيوي.<br />إذا كانت لديك أية أسئلة إضافية حول استخدام الدواء، فاستشر الطبيب أو الصيدلي الخاص بك.<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يسبب فلوكساسين أعراضاً جانبية، عى الرغم من أنها لا تحدث لدى الجميع.<br />ٌّ إذا أصبحـت أي مـن الأعـراض الجانبيـة خطـيرة، أو إذا لاحظـت أيَّـة أعـراض جانبيـة غـير واردة بهـذه النـشرة، يُرجـى إبلاغ الطبيـب أو<br />الصيـدلي الخـاص بـك.<br /><strong>&bull; أعراض جانبية شائعة (بين 1 و 10 من كل 100 شخص من المحتمل أن يصابوا بهذه الأعراض:)</strong><br />غثيان وإسهال.<br />آلام المفاصل والتهاب المفاصل في الأطفال.<br /><strong>&bull; أعراض جانبية غير شائعة (بين 1 و 10 من كل 1000 شخص من المحتمل أن يصابوا بهذه الأعراض:)</strong><br />عدوى فطرية إضافية.<br />مستويات مرتفعة من خلايا اليوزينيات، وهو نوع من خلايا الدم البيضاء.<br />فقدان الشهية.<br />فرط النشاط أو هياج.<br />صداع ودوخة ومشاكل في النوم، أو اضطرابات في التذوق.<br />قيء وآلام في البطن ومشاكل في الجهاز الهضمي مثل اضطراب في المعدة (عسر الهضم/الحرقة،) أو ريح (انتفاخ.)<br />زيادة كميات بعض المواد في الدم (ناقلات الأمين و/ و بيليروبين.)<br />طفح جلدي، حكة، أو شرى (ارتكاريا.)<br />آلام المفاصل في البالغين.<br />خلل في وظائف الكلى.<br />آلام في العضلات والعظام، والشعور بالإعياء (و َهن،) أو حمى.<br />زيادة إنزيم الفوسفاتيز القلوي في الدم (مادة معينة توجد في الدم.)<br /><strong>&bull; أعراض جانبية نادرة (بين 1 و 10 من كل 10000 شخص من المحتمل أن يصابوا بهذه الأعراض:)</strong><br />التهـاب الأمعـاء (التهـاب القولـون) باسـتخدام المضـادات الحيويـة (يمكـن أن تكـون مميتـة في حـالات نـادرة جـدا) (انظـر القسـم :3تـوخ<br />ً حـذرا خاصـا مع فلوكساسـين.)<br />تغـيرات في تعـداد خلايـا الـدم (قلـة الكريـات البيـض، زيـادة عـدد الكريـات البيضاء، قلـة العـدلات، وفقر الـدم،) زيادة أو نقـص في عوامل<br />تخثر الـدم (الصفائـح الدموية.)<br />تفاعلات حساسية، تورم (وذمة،) أو تورم سريع في الجلد والأغشية المخاطية (وذمة وعائية)<br />زيادة نسبة السكر في الدم (فرط سكر الدم.)<br />خفـض مسـتويات السـكر في الـدم (نقـص سـكر الـدم) و تشـمل علامـات نقـص السـكر في الـدم ، الارتبـاك، النبـض سريـع جـدا، الدوخـة ،<br />بـشرة شـاحبة، التعـرق، جـوع غـير عـادي، الارتجـاف، الصـداع، الضعف ، والتهيـج و قلق غير عادي. نقص سـكر الـدم قد يـؤدي الى غيبوبة<br />ارتباك، توهان، تفاعلات ناتجة عن القلق، وأحلام غريبة، واكتئاب، أو هلوسة.<br />الشـعور بإحسـاس كالوخز/ كالآبر، حساسـية غير معتادة لمنبهات الحواس، انخفاض حساسـية الجلد، والرعشـة، والتشـنجات (انظر القسـم<br />: ً 3تـوخ حـذرا خاصا مع فلوكساسـين ُ ،) أو دوار (دوخة.)<br />الاضطرابات في الانتباه ، والعصبية ، وضعف الذاكرة ، والاضطرابات الخطيرة في القدرات العقلية تدعي الهذيان.<br />مشاكل بالإبصار<br />الطنين، فقدان السمع، قصور بحاسة السمع.<br />ُّ سرعة ضربات القلب (تسرع القلب.)<br />توسيع الأوعية الدموية (توسع الأوعية،) وانخفاض ضغط الدم، أو إغماء.<br />ضيق في التنفس، بما في ذلك أعراض الربو.<br />اضطرابات في الكبد، واليرقان (اليرقان الركودي،) أو التهاب الكبد.<br />حساسية تجاه الضوء (انظر القسم : ً 2توخ حذرا خاصا مع فلوكساسين.)<br />آلام في العضات، التهاب المفاصل، وزيادة في التوتر و/أو التمزق العضلي.<br />فشل كلوي، ظهور دم أو بلورات في البول (انظر القسم : ً 2توخ حذرا خاصا مع فلوكساسين ،) والتهاب الجهاز البولي.<br />احتباس السوائل أو فرط التعرق<br />مستويات غير طبيعية لعامل التخثر (بروثرومبين) أو زيادة مستويات إنزيم الأمياز<br /><strong>&bull; أعراض جانبية نادرة جدا (أقل من 1 من كل 10000 شخص من المحتمل أن يصابوا بهذه الأعراض:)</strong><br />نـوع محـدد مـن انخفـاض عـدد كريـات الـدم الحمـراء (فقـر الـدم الانحـلالي،) وانخفـاض خطـير بأحـد أنـواع خلايـا الـدم البيضـاء (نـدرة<br />المحببـات،) وانخفـاض في عـدد خلايـا الـدم الحمـراء والبيضـاء والصفائـح الدموية (قلة الكريـات الشـاملة،) والتي قد تكون مميتـة، وتثبيط<br />النخـاع العظمـي، والـذي قـد يكـون مميتًـا أيضـا (انظـر القسـم : ً 2تـوخ حـذرا خاصا مع فلوكساسـين)<br />تفاعـلات حساسـية شـديدة (تفاعـل تأقـي &laquo;حساسـية شـديدة&raquo; أو صدمـة تأقيـة، والتـي يمكن أن تكـون مميتـة- داء المصل) (انظر القسـم<br />: ً 2تـوخ حـذرا خاصا مع فلوكساسـين.)<br />اضطرابات عقلية (تفاعلات ذهانية) (انظر القسم : ً 2توخ حذرا خاصا مع فلوكساسين.)<br />صداع نصفي، واضطرابات التناسق الحركي، مشي غير متزن (اضطرابات المشي،) اضطرابات بحاسة الشم، وارتفاع بضغط المخ.<br />اضطرابات في رؤية الألوان.<br />التهاب في جدار الأوعية الدموية (التهاب وعائي.)<br />التهاب البنكرياس.<br />موت خلاًيا الكبد (نخر الكبد) ونادرا جدا قد يؤدي ذلك إلى فشل كبدي يهدد الحياة.<br />نزيـف تنقيطـي تحـت الجلـد في شـكل ناقط دبوسـية صغـيرة (حبرات)؛ طفـح جلدي متنوع (على سـبيل المثال، متلازمة سـتيفنز جونسـون<br />أو انحـلال البـشرة النخري التسـممي واللـذان من المحتمـل أن يكونا مميتين.)<br />ضعـف العضلات، والتهـاب الأوتـار، وتمـزق الأوتـار - وخاصـة في وتـر كبـير في الجـزء الخلفي مـن الكاحل (وتـر العرقوب) (انظر القسـم :3<br />ً تـوخ حـذرا خاصـا مـع فلوكساسـين)؛ تدهـور أعـراض الوهن العضـلي الوبيل (انظـر القسـم : ً 2توخ حـذرا خاصا مع فلوكساسـين.)<br /><strong>&bull; نسبة الحدوث غير معروفة (لا يمكن تقديرها من البيانات المتاحة.)</strong><br />سرعة ضربات القلب غير الطبيعية ، عدم انتظام ضربات القلب المهددة للحياة ، تغير في نظم القلب<br />(يُسمى &laquo;إطالة فترة ، &raquo;QTيُرى على مخطط كهربية القلب ، النشاط الكهربائي للقلب)<br />- التأثير على تخثر الدم (في المرضى المعالجين بمضادات فيتامين ك)<br />- الشعور بالحماس الشديد (الهوس) أو الشعور بالتفاؤل الكبير والنشاط الزائد (الهوس الخفيف.)<br />- المتلازمة المصاحبة لضعف إفراز الماء وانخفاض مستويات الصوديوم SIADH<br />- فقدان الوعي نتيجة النقص الشديد في مستويات السكر في الدم (غيبوبة سكر الدم.)<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ً يحفظ بعيدا عن متناول ورؤية الأطفال.<br />يخزن في درجة حرارة أقل من 30 درجة مئوية.<br />لا تَستخدم فلوكساسين بعد انتهاء تاريخ الصلاحية المدون على العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.<br />يجـب عـدم التخلـص مـن الأدويـة عـن طريق ميـاه الصرف أو مـع المخلفـات المنزلية. اسـتشر الصيدلي الخاص بـك عن كيفيـة التخلص من<br />الأدويـة التـي لم تعـد بحاجة إليها. ستسـاعد هـذه الإجراءات في حمايـة البيئة.<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي سيبروفلوكساسين.<br />يحتوي كل قرص مغلف على سيبروفلوكساسين (في هيئة هيدروكلوريد.) وهو ما يعادل 500 ملج من المادة الفعالة سيبروفلوكساسين.<br />المكونات الأخرى هي:<br />آفيسـيل( ، )PH102نشـا الـذرة، كـروس كارميلـوز الصوديـوم، بوليسـوربات( ،)80بوفيـدون( ، )K30صوديـوم جلايكـولات النشـا، تلـك،<br />ايروسـيل، وسـتيرات الماغنسـيوم، أوبـادري أبيـض</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقـراص فلوكساسـين 500 ملج: أقـراص مغلفـة مسـتديره وثنائيـة التحـدب بيضـاء الى ابيـض مائـل للأصفـر. منقـوش الرمـزSJ125 عـلى<br />أحـد جانبيها.<br />تحتوي كل عبوة عى 10 أقراص</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة ساجا الصيدلانية<br />الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة<br />جدة - المملكة العربية السعودية<br /><strong>لأية معلومات عن فلوكساسين، يُرجى الاتصال بـ</strong><br />الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة<br />جدة - المملكة العربية السعودية<br />ص.ب: ،42600جدة ،21551المملكة العربية السعودية<br />+ 966 12 6066667 : تليفون<br />sajapharma.com<br />تمت آخر مراجعة لهذه النشرة في {أبريل/2023؛ رقم الإصدار {}00<br /><strong>للإبلاغ عن الأعراض الجانبية</strong><br /><strong>&bull; المملكة العربية السعودية</strong><br />المركز الوطني للتيقظ والسامة الدوائية<br />- مركز اتصال هيئة الغذاء والدواء : 19999<br />npc.drug@sfda.gov.sa :- البريد الإلكتروني<br />https://ade.sfda.gov.sa :- الموقع الإلكتروني<br /><strong>&bull; دول الخليج الأخرى/الدول الأخرى</strong><br />- الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أبريل/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Floxacin 500 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 500 mg ciprofloxacin (as hydrochloride).
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                White to almost white biconvex film Coated tab. Coded by (SJ125) in one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Floxacin 500 mg film-coated tablets are indicated for the treatment of the following<br />infections (see sections 4.4 and 5.1). Special attention should be paid to available<br />information on resistance to ciprofloxacin before commencing therapy.<br />Consideration should be given to official guidance on the appropriate use of<br />antibacterial agents.<br />Adults<br />&bull; Lower respiratory tract infections due to Gram-negative bacteria<br />- exacerbations of chronic obstructive pulmonary disease<br />- broncho-pulmonary infections in cystic fibrosis or in bronchiectasis<br />- pneumonia<br />&bull; Chronic suppurative otitis media<br />&bull; Acute exacerbation of chronic sinusitis especially if these are caused by Gramnegative bacteria<br />&bull; Urinary tract infections<br />&bull; Gonococcal uretritis and cervicitis<br />&bull; Epididymo-orchitis including cases due to Neisseria gonorrhoeae<br />&bull; Pelvic inflammatory disease including cases due to Neisseria gonorrhoeae<br />In the above genital tract infections when thought or known to be due to Neisseria<br />gonorrhoeae it is particularly important to obtain local information on the<br />prevalence of resistance to ciprofloxacin and to confirm susceptibility based on<br />laboratory testing.<br />&bull; Infections of the gastro-intestinal tract (e.g. travellers&#39; diarrhoea)<br />&bull; Intra-abdominal infections<br />&bull; Infections of the skin and soft tissue caused by Gram-negative bacteria<br />&bull; Malignant external otitis<br />&bull; Infections of the bones and joints<br />&bull; Treatment of infections in neutropenic patients<br />&bull; Prophylaxis of infections in neutropenic patients<br />&bull; Prophylaxis of invasive infections due to Neisseria meningitidis<br />&bull; Inhalation anthrax (post-exposure prophylaxis and curative treatment)<br />Children and adolescents<br />&bull; Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa<br />&bull; Complicated urinary tract infections and pyelonephritis<br />&bull; Inhalation anthrax (post-exposure prophylaxis and curative treatment)<br />Ciprofloxacin may also be used to treat severe infections in children and adolescents<br />when this is considered to be necessary.<br />Treatment should be initiated only by physicians who are experienced in the<br />treatment of cystic fibrosis and/or severe infections in children and adolescents (see<br />sections 4.4 and 5.1).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dosage is determined by the indication, the severity and the site of the infection, the susceptibility to ciprofloxacin of the causative organism(s), the renal function of the patient and, in children and adolescents the body weight.</p><p>The duration of treatment depends on the severity of the illness and on the clinical and bacteriological course.</p><p>&nbsp;</p><p>Treatment of infections due to certain bacteria (e.g. <em>Pseudomonas aeruginosa</em>, <em>Acinetobacter </em>or <em>Staphylococci</em>) may require higher ciprofloxacin doses and co- administration with other appropriate antibacterial agents.</p><p>Treatment of some infections (e.g. pelvic inflammatory disease, intra-abdominal infections, infections in neutropenic patients and infections of bones and joints) may require co-administration with other appropriate antibacterial agents depending on the pathogens involved.</p><p><em><u>Adults</u></em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose in mg</strong></p></td><td style="vertical-align:top"><p><strong>Total duration of treatment (potentially including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; initial parenteral treatment with ciprofloxacin)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections of the lower respiratory tract</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Infections of the upper respiratory tract</p></td><td style="vertical-align:top"><p>Acute exacerbation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of chronic sinusitis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Chronic suppurative&nbsp;&nbsp;&nbsp; otitis media</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Malignant external otitis</p></td><td style="vertical-align:top"><p>750 mg twice daily</p></td><td style="vertical-align:top"><p>28 days up to 3 months</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Urinary&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tract infections</p></td><td rowspan="2" style="vertical-align:top"><p>Uncomplicated cystitis</p></td><td style="vertical-align:top"><p>250 mg twice daily to 500 mg twice daily</p></td><td style="vertical-align:top"><p>3 days</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>In pre-menopausal women, 500 mg single dose may be used</p></td></tr><tr><td style="vertical-align:top"><p>Complicated cystitis, Uncomplicated pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>7 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>at least 10 days, it can be continued for longer than 21 days in some specific circumstances (such as abscesses)</p></td></tr><tr><td style="vertical-align:top"><p>Prostatitis</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>2 to 4 weeks (acute) to</p><p>4 to 6 weeks (chronic)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Genital&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tract infections</p></td><td style="vertical-align:top"><p>Gonococcal uretritis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and cervicitis</p></td><td style="vertical-align:top"><p>500 mg as a single dose</p></td><td style="vertical-align:top"><p>1 day (single dose)</p></td></tr><tr><td style="vertical-align:top"><p>Epididymo-orchitis and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pelvic</p><p>inflammatory diseases</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>at least 14 days</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Infections of the gastro-intestinal tract and intra- abdominal infections</p></td><td style="vertical-align:top"><p>Diarrhoea caused by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial pathogens including&nbsp;&nbsp;&nbsp; <em>Shigella </em>spp.&nbsp;&nbsp;&nbsp;&nbsp; other&nbsp;&nbsp;&nbsp; than <em>Shigella dysenteriae </em>type 1 and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; empirical treatment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of severe&nbsp;&nbsp;&nbsp;&nbsp; travellers&#39; diarrhoea</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>1 day</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea caused by&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Shigella dysenteriae </em>type 1</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>5 days</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea&nbsp;&nbsp;&nbsp; caused by <em>Vibrio cholerae</em></p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>3 days</p></td></tr><tr><td style="vertical-align:top"><p>Typhoid fever</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>7 days</p></td></tr><tr><td style="vertical-align:top"><p>Intra-abdominal infections due to Gram-negative bacteria</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>5 to 14 days</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Infections of the skin and soft tissue</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>7 to 14 days</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Bone and joint infections</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>max. of 3 months</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Treatment of infections or prophylaxis of infections in neutropenic patients</p><p>Ciprofloxacin should be co- administered with appropriate antibacterial agent(s) in accordance to official guidance.</p></td><td style="vertical-align:top"><p>500 mg twice daily to 750 mg twice daily</p></td><td style="vertical-align:top"><p>Therapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; should&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; be continued&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; over&nbsp;&nbsp;&nbsp;&nbsp; the entire&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; period&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of neutropenia</p></td></tr></tbody></table><p><!--[if gte vml 1]><o:wrapblock><v:shape id="_x0000_s1026"
  style='position:absolute;margin-left:85.95pt;margin-top:745.55pt;width:422.35pt;
  height:.25pt;z-index:15731200;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordorigin="1719,14911" coordsize="8447,5"
  o:spt="100" adj="0,,0" path="m5519,14911r-3800,l1719,14916r3800,l5519,14911xm7634,14911r-2101,l5533,14916r2101,l7634,14911xm10166,14911r-2518,l7648,14916r2518,l10166,14911xe"
  fillcolor="#9f9f9f" stroked="f">
  <v:stroke joinstyle="round"/>
  <v:formulas/>
  <v:path arrowok="t" o:connecttype="segments"/>
  <w:wrap anchorx="page" anchory="page"/>
 </v:shape><![endif]--><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Prophylaxis of invasive infections due to <em>Neisseria meningitidis</em></p></td><td style="vertical-align:top"><p>500 mg as a single dose</p></td><td style="vertical-align:top"><p>1 day (single dose)</p></td></tr><tr><td style="vertical-align:top"><p>Inhalation&nbsp;&nbsp;&nbsp;&nbsp; anthrax&nbsp;&nbsp;&nbsp;&nbsp; post-exposure</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td><td style="vertical-align:top"><p>60&nbsp;&nbsp;&nbsp;&nbsp; days&nbsp;&nbsp;&nbsp;&nbsp; from&nbsp;&nbsp;&nbsp;&nbsp; the</p></td></tr><tr><td style="vertical-align:top"><p>prophylaxis and curative treatment</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>confirmation of <em>Bacillus</em></p></td></tr><tr><td style="vertical-align:top"><p>for persons able to receive treatment</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>anthracis </em>exposure</p></td></tr><tr><td style="vertical-align:top"><p>by&nbsp;&nbsp;&nbsp;&nbsp; oral&nbsp;&nbsp;&nbsp;&nbsp; route&nbsp;&nbsp;&nbsp;&nbsp; when&nbsp;&nbsp;&nbsp;&nbsp; clinically</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>appropriate.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Drug administration should begin as</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>soon as possible after suspected or</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>confirmed exposure.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><em><u>Children and adolescents</u></em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indications</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose in mg</strong></p></td><td style="vertical-align:top"><p><strong>Total&nbsp;&nbsp; duration&nbsp;&nbsp; of treatment (potentially including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; initial parenteral treatment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with ciprofloxacin)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cystic fibrosis</p></td><td style="vertical-align:top"><p>20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>10 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tract infections&nbsp;&nbsp;&nbsp;&nbsp; and pyelonephritis</p></td><td style="vertical-align:top"><p>10 mg/kg body weight twice daily to 20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>10 to 21 days</p></td></tr><tr><td style="vertical-align:top"><p>Inhalation</p></td><td style="vertical-align:top"><p>10 mg/kg body weight twice daily to 15</p></td><td style="vertical-align:top"><p>60&nbsp; &nbsp;days from&nbsp; &nbsp;the</p></td></tr><tr><td style="vertical-align:top"><p>anthrax&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; post-</p></td><td style="vertical-align:top"><p>mg/kg&nbsp; &nbsp;body&nbsp; &nbsp;weight&nbsp; &nbsp;twice&nbsp; &nbsp;daily&nbsp; &nbsp;with&nbsp; &nbsp;a</p></td><td style="vertical-align:top"><p>confirmation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of</p></td></tr><tr><td style="vertical-align:top"><p>exposure</p></td><td style="vertical-align:top"><p>maximum of 500 mg per dose.</p></td><td style="vertical-align:top"><p><em>Bacillus&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anthracis</em></p></td></tr><tr><td style="vertical-align:top"><p>prophylaxis and</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>exposure</p></td></tr><tr><td style="vertical-align:top"><p>curative</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>treatment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>persons able to</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>receive</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>treatment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>oral route when</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>clinically</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>appropriate.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Drug</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>administration</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>should begin as</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>soon as possible</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>after suspected</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confirmed</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>exposure.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Other&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe infections</p></td><td style="vertical-align:top"><p>20 mg/kg body weight twice daily with a maximum of 750 mg per dose.</p></td><td style="vertical-align:top"><p>According&nbsp;&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp; the type of infections</p></td></tr></tbody></table><p><em><u>Geriatric patients</u></em></p><p>Geriatric patients should receive a dose selected according to the severity of the infection and the patient&#39;s creatinine clearance.</p><p><em><u>Renal and hepatic impairment</u></em></p><p>Recommended starting and maintenance doses for patients with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine Clearance [mL/min/1.73 m&sup2;]</strong></p></td><td style="vertical-align:top"><p><strong>Serum Creatinine [&micro;mol/L]</strong></p></td><td style="vertical-align:top"><p><strong>Oral Dose [mg]</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 60</p></td><td style="vertical-align:top"><p>&lt; 124</p></td><td style="vertical-align:top"><p>See Usual Dosage.</p></td></tr><tr><td style="vertical-align:top"><p>30&nbsp;&nbsp;&nbsp; 60</p></td><td style="vertical-align:top"><p>124 to 168</p></td><td style="vertical-align:top"><p>250&nbsp;&nbsp;&nbsp; 500 mg every 12 h</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>&gt; 169</p></td><td style="vertical-align:top"><p>250&nbsp;&nbsp;&nbsp; 500 mg every 24 h</p></td></tr><tr><td style="vertical-align:top"><p>Patients on haemodialysis</p></td><td style="vertical-align:top"><p>&gt; 169</p></td><td style="vertical-align:top"><p>250&nbsp;&nbsp;&nbsp; 500 mg every 24 h (after dialysis)</p></td></tr><tr><td style="vertical-align:top"><p>Patients on peritoneal dialysis</p></td><td style="vertical-align:top"><p>&gt; 169</p></td><td style="vertical-align:top"><p>250&nbsp;&nbsp;&nbsp; 500 mg every 24 h</p></td></tr></tbody></table><p>In patients with impaired liver function no dose adjustment is required.</p><p>Dosing in children with impaired renal and/or hepatic function has not been studied.</p><p><em><u>Method of administration</u></em></p><p>Tablets are to be swallowed unchewed with fluid. They can be taken independent of mealtimes. If taken on an empty stomach, the active substance is absorbed more rapidly. Ciprofloxacin tablets should not be taken with dairy products (e.g. milk, yoghurt) or mineral-fortified fruit-juice (e.g. calcium-fortified orange juice) (see section 4.5).</p><p>In severe cases or if the patient is unable to take tablets (e.g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance, to other quinolones or to any of the excipients (see section 6.1).
•	Concomitant administration of ciprofloxacin and tizanidine (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Severe infections and mixed infections with Gram-positive and anaerobic pathogens</u></em><em> </em>Ciprofloxacin monotherapy is not suited for treatment of severe infections and infections that might be due to Gram-positive or anaerobic pathogens. In such infections&nbsp; ciprofloxacin&nbsp;&nbsp; must&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; co-administered&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with&nbsp;&nbsp;&nbsp;&nbsp; other&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; appropriate antibacterial agents.</p><p><em><u>Streptococcal</u></em><em><u> </u></em><em><u>Infections (including Streptococcus pneumoniae)</u></em></p><p>Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy<em>.</em></p><p>&nbsp;</p><p><em><u>Genital tract infections</u></em></p><p>Epididymo-orchitis and pelvic inflammatory diseases may be caused by fluoroquinolone-resistant <em>Neisseria gonorrhoeae</em>. Ciprofloxacin should be co- administered with another appropriate antibacterial agent unless ciprofloxacin- resistant <em>Neisseria gonorrhoeae </em>can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.</p><p><em><u>Intra-abdominal infections</u></em></p><p>There are limited data on the efficacy of ciprofloxacin in the treatment of post- surgical intra-abdominal infections.</p><p><em><u>Travellers&#39; diarrhoea</u></em></p><p>The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.</p><p><em><u>Infections of the bones and joints</u></em></p><p>Ciprofloxacin should be used in combination with other antimicrobial agents depending on the results of the microbiological documentation.</p><p><em><u>Inhalational anthrax</u></em></p><p>Use in humans is based on <em>in-vitro </em>susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.</p><p><em><u>Children and adolescents</u></em></p><p>The use of ciprofloxacin in children and adolescents should follow available official guidance. Ciprofloxacin treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.</p><p>Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals. Safety data from a randomised double-blind study on ciprofloxacin use in children (ciprofloxacin: n=335, mean age = 6.3 years; comparators: n=349, mean age = 6.2 years; age range = 1 to 17 years) revealed an incidence of suspected drug-related arthropathy (discerned from joint-related clinical signs and symptoms) by Day +42 of 7.2% and 4.6%. Respectively, an incidence of drug-related arthropathy by 1-year follow-up was 9.0% and 5.7%. The increase of suspected drug-related arthropathy cases over time was not statistically significant between groups. Treatment should be initiated only after a careful benefit/risk evaluation, due to possible adverse events related to joints and/or surrounding tissue.</p><p><em>Broncho-pulmonary infections in cystic fibrosis</em></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.png" o:spid="_x0000_s1027" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:387.85pt;
 margin-top:5.8pt;width:3.9pt;height:.65pt;z-index:-16628224;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="5" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />Clinical trials have included children and adolescents aged 5 17 years. More limited experience is available in treating children between 1 and 5 years of age.</p><p><em>Complicated urinary tract infections and pyelonephritis</em></p><p>Ciprofloxacin treatment of urinary tract infections should be considered when other treatments cannot be used, and should be based on the results of the microbiological documentation.</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1026" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:385.35pt;
 margin-top:5.45pt;width:3.9pt;height:.65pt;z-index:-16627712;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="5" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />Clinical trials have included children and adolescents aged 1 17 years.</p><p><em>Other specific severe infections</em></p><p>Other severe infections in accordance with official guidance, or after careful benefit- risk evaluation&nbsp; when&nbsp; other treatments cannot be used, or after failure to</p><p>&nbsp;</p><p>conventional therapy and when the microbiological documentation can justify a ciprofloxacin use.</p><p>The use of ciprofloxacin for specific severe infections other than those mentioned above has not been evaluated in clinical trials and the clinical experience is limited. Consequently, caution is advised when treating patients with these infections.</p><p><em><u>Hypersensitivity</u></em></p><p>Hypersensitivity and allergic reactions, including anaphylaxis and anaphylactoid reactions, may occur following a single dose (see section 4.8) and may be life- threatening. If such reaction occurs, ciprofloxacin should be discontinued and an adequate medical treatment is required.</p><p><em><u>Musculoskeletal System</u></em></p><p>Ciprofloxacin should generally not be used in patients with a history of tendon disease/disorder related to quinolone treatment. Nevertheless, in very rare instances, after microbiological documentation of the causative organism and evaluation of the risk/benefit balance, ciprofloxacin may be prescribed to these patients for the treatment of certain severe infections, particularly in the event of failure of the standard therapy or bacterial resistance, where the microbiological data may justify the use of ciprofloxacin.</p><p>Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, as soon as the first 48 hours of treatment. The risk of tendinopathy may be increased in elderly patients or in patients concomitantly treated with corticosteroids (see section 4.8).</p><p>At any sign of tendinitis (e.g. painful swelling, inflammation), ciprofloxacin treatment should be discontinued. Care should be taken to keep the affected limb at rest.</p><p>Ciprofloxacin should be used with caution in patients with myasthenia gravis (see section 4.8).</p><p><em><u>&nbsp;Vision disorders</u></em></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately.</p><p><em><u>Photosensitivity</u></em></p><p>Ciprofloxacin has been shown to cause photosensitivity reactions. Patients taking ciprofloxacin should be advised to avoid direct exposure to either extensive sunlight or UV irradiation during treatment (see section 4.8).</p><p><em><u>Central Nervous System</u></em></p><p>Quinolones are known to trigger seizures or lower the seizure threshold. Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure. If seizures occur ciprofloxacin should be discontinued (see section 4.8). Psychiatric reactions may occur even after the first administration of ciprofloxacin. In rare cases, depression or psychosis can progress to self-endangering behaviour. In these cases, ciprofloxacin should be discontinued.</p><p>Cases of polyneuropathy (based on neurological symptoms such as pain, burning, sensory disturbances or muscle weakness, alone or in combination) have been reported in patients receiving ciprofloxacin. Ciprofloxacin should be discontinued in patients experiencing symptoms of neuropathy, including pain, burning, tingling, numbness, and/or weakness in order to prevent the development of an irreversible condition (see section 4.8).</p><p><em><u>Cardiac disorders</u></em></p><p>Caution should be taken when using fluoroquinolones, including ciprofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><p>&bull;&nbsp; congenital long QT syndrome</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics)</p><p>&bull;&nbsp; uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)</p><p>&bull;&nbsp; cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)</p><p>Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including ciprofloxacin, in these populations. (See section 4.2 Elderly patients, section 4.5, section 4.8, section 4.9).</p><p>&nbsp;</p><p><em><u>Dysglycaemia</u></em></p><p><em><u>As with all quinolones, disturbances in blood glucose, including both hypoglycaemia</u></em><em> </em><em><u>and hyperglycaemia have been reported, usually in diabetic patients receiving</u></em><em> </em><em><u>concomitant treatment with an oral hypoglycaemic agent (e.g., glibenclamide) or with</u></em><em> </em><em><u>insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful</u></em><em> </em><em><u>monitoring of blood glucose is recommended (see section 4.8).</u></em></p><p><em><u>Gastrointestinal System</u></em></p><p>The occurrence of severe and persistent diarrhoea during or after treatment (including several weeks after treatment) may indicate an antibiotic-associated colitis (life-threatening with possible fatal outcome), requiring immediate treatment (see section 4.8). In such cases, ciprofloxacin should immediately be discontinued, and an appropriate therapy initiated. Anti-peristaltic drugs are contraindicated&nbsp; &nbsp;in this situation.</p><p><em><u>Renal and urinary system</u></em></p><p>Crystalluria related to the use of ciprofloxacin has been reported (see section 4.8). Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.</p><p><em><u>Hepatobiliary system</u></em></p><p>Cases of hepatic necrosis and life-threatening hepatic failure have been reported with ciprofloxacin (see section 4.8). In the event of any signs and symptoms of hepatic disease (such as anorexia, jaundice, dark urine, pruritus, or tender abdomen), treatment should be discontinued.</p><p><em><u>Glucose-6-phosphate dehydrogenase deficiency</u></em></p><p>Haemolytic reactions have been reported with ciprofloxacin in patients with glucose- 6-phosphate dehydrogenase deficiency. Ciprofloxacin should be avoided in these patients unless the potential benefit is considered to outweigh the possible risk. In this case,potential occurrence of haemolysis should be monitored.</p><p><em><u>Resistance</u></em></p><p>During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection. There may be a particular risk of selecting for ciprofloxacin- resistant bacteria during extended durations of treatment and when treating nosocomial infections and/or infections caused by <em>Staphylococcus </em>and <em>Pseudomonas </em>species.</p><p><em><u>Cytochrome P450</u></em></p><p>Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, ropinirole, tizanidine). Co-administration of ciprofloxacin and tizanidine is contra-indicated. Therefore, patients taking these substances concomitantly with ciprofloxacin should be monitored closely for clinical signs of overdose, and determination of serum concentrations (e.g. of theophylline) may be necessary (see section 4.5).</p><p><em><u>Methotrexate</u></em></p><p>The concomitant use of ciprofloxacin with methotrexate is not recommended (see section 4.5).</p><p><em><u>Interaction with tests</u></em></p><p>The in-vitro activity of ciprofloxacin against Mycobacterium tuberculosis might give false negative bacteriological test results in specimens from patients currently taking ciprofloxacin.</p><p>Aortic aneurysm and dissection, and heart valve regurgitation/incompetence Epidemiologic studies report an increased risk of aortic aneurysm and dissection,</p><p>&nbsp;</p><p>particularly in elderly patients, and of aortic and mitral valve regurgitation after intake of fluoroquinolones. Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.8).</p><p>Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or congenital heart valve disease, or in patients diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or heart valve disease, or in presence of other risk factors or conditions predisposing</p><p>-&nbsp; for aortic aneurysm and dissection and heart valve regurgitation/ incompetence (e.g. connective tissue disorders such as Marfan syndrome, Ehlers-Danlos syndrome, Turner syndrome, Behcet&#39;s disease, hypertension, rheumatoid arthritis).</p><p>-&nbsp; for aortic aneurysm and dissection (e.g. vascular disorders such as Takayasu arteritis or giant cell arteritis, or known atherosclerosis, or Sj&ouml;gren&#39;s syndrome) or additionally</p><p>-&nbsp; for heart valve regurgitation/incompetence (e.g. infective endocarditis).</p><p>The risk of aortic aneurysm and dissection, and their rupture may also be increased in patients treated concurrently with systemic corticosteroids.</p><p>In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p><p>Patients should be advised to seek immediate medical attention in case of acute dyspnoea, new onset of heart palpitations, or development of oedema of the abdomen or lower extremities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Effects of other products on ciprofloxacin:</u></em></p><p><em><u>Drugs known to prolong QT interval</u></em></p><p>Ciprofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Chelation Complex Formation</u></em></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.png" o:spid="_x0000_s1026" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:230.9pt;
 margin-top:80.9pt;width:4.5pt;height:.75pt;z-index:-16627200;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />The simultaneous administration of ciprofloxacin (oral) and multivalent cation- containing drugs and mineral supplements (e.g. calcium, magnesium, aluminium, iron), polymeric phosphate binders (e.g. sevelamer or lanthanum carbonate), sucralfate or antacids, and highly buffered drugs (e.g. didanosine tablets) containing magnesium, aluminium, or calcium reduces the absorption of ciprofloxacin. Consequently, ciprofloxacin should be administered either&nbsp;&nbsp; 1&nbsp;&nbsp; 2 hours before or at least&nbsp;&nbsp;&nbsp; 4&nbsp;&nbsp;&nbsp; hours&nbsp; &nbsp;after&nbsp;&nbsp;&nbsp; these preparations. The restriction does not apply to antacids belonging to the class of H2 receptor blockers.</p><p><em><u>Food and Dairy Products</u></em></p><p>Dietary calcium as part of a meal does not significantly affect absorption. However, the concurrent administration of dairy products or mineral-fortified drinks alone (e.g. milk, yoghurt, calcium-fortified orange juice) with ciprofloxacin should be avoided because absorption of ciprofloxacin may be reduced.</p><p><em><u>Probenecid</u></em></p><p>Probenecid interferes with renal secretion of ciprofloxacin. Co-administration of probenecid and ciprofloxacin increases ciprofloxacin serum concentrations.</p><p><em><u>Metoclopramide</u></em></p><p>Metoclopramide accelerates the absorption of ciprofloxacin (oral) resulting in a shorter time to reach maximum plasma concentrations. No effect was seen on the bioavailability of ciprofloxacin.</p><p><em><u>Omeprazole</u></em></p><p>Concomitant administration of ciprofloxacin and omeprazole containing medicinal products results in a slight reduction of Cmax and AUC of ciprofloxacin</p><p><em><u>Effects of ciprofloxacin on other medicinal products:</u></em></p><p><em><u>Tizanidine</u></em></p><p>Tizanidine must not be administered together with ciprofloxacin (see section 4.3). In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (Cmax increase: 7-fold, range: 4 to 21-fold; AUC increase: 10-fold, range: 6 to 24-fold) when given concomitantly with ciprofloxacin. Increased serum tizanidine concentration is associated with a potentiated hypotensive and sedative effect.</p><p>&nbsp;</p><p><em><u>Agomelatine</u></em></p><p>In clinical studies, it was demonstrated that fluvoxamine, as a strong inhibitor of the CYP450 1A2 isoenzyme, markedly inhibits the metabolism of agomelatine resulting in a 60- fold increase of agomelatine exposure. Although no clinical data are available for a possible interaction with ciprofloxacin, a moderate inhibitor of CYP450 1A2, similar effects can be expected upon concomitant administration (see &#39;Cytochrome P450&#39; in section 4.4).</p><p>&nbsp;</p><p><em><u>Methotrexate</u></em></p><p>Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk of methotrexate-associated toxic reactions. The concomitant use is not recommended (see section 4.4).</p><p><em><u>Theophylline</u></em></p><p>Concurrent administration of ciprofloxacin and theophylline can cause an undesirable increase in serum theophylline concentration. This can lead to theophylline-induced side effects that may rarely be life threatening or fatal. During the combination, serum theophylline concentrations should be checked and the</p><p>&nbsp;</p><p>theophylline dose reduced as necessary (see section 4.4).</p><p><em><u>Other xanthine derivatives</u></em></p><p>On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.</p><p><em><u>Phenytoin</u></em></p><p>Simultaneous administration of ciprofloxacin and phenytoin may result in increased or reduced serum levels of phenytoin such that monitoring of drug levels is recommended.</p><p><em><u>Cyclosporin</u></em></p><p>A transient rise in the concentration of serum creatinine was observed when ciprofloxacin and cyclosporin containing medicinal products were administered simultaneously. Therefore, it is frequently (twice a week) necessary to control the serum creatinine concentrations in these patients.</p><p><em><u>Oral anticoagulants</u></em></p><p>Simultaneous administration of ciprofloxacin with warfarin may augment its anti- coagulant effects. There have been many reports of increases in oral anticoagulant activity in patients receiving antibacterial agents, including fluoroquinolones. The</p><p>&nbsp;</p><p>risk may vary with the underlying infection, age and general status of the patient so that the contribution of the fluoroquinolone to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of ciprofloxacin with an oral anticoagulant agent.</p><p><em><u>Duloxetine</u></em></p><p>In clinical studies, it was demonstrated that concomitant use of duloxetine with strong inhibitors of the CYP450 1A2 isozyme such as fluvoxamine, may result in an increase of AUC and Cmax of duloxetine. Although no clinical data are available on a possible interaction with ciprofloxacin, similar effects can be expected upon concomitant administration (see section 4.4).</p><p><em><u>Ropinirole</u></em></p><p>It was shown in a clinical study that concomitant use of ropinirole with ciprofloxacin, a moderate inhibitor of the CYP450 1A2 isozyme, results in an increase of Cmax and AUC of ropinirole by 60% and 84%, respectively. Monitoring of ropinirole-related side effects and dose adjustment as appropriate is recommended during and shortly after co-administration with ciprofloxacin (see section 4.4).</p><p>&nbsp;</p><p><em><u>Lidocaine</u></em></p><p>It was demonstrated in healthy subjects that concomitant use of lidocaine containing medicinal products with ciprofloxacin, a moderate inhibitor of CYP450 1A2 isozyme, reduces clearance of intravenous lidocaine by 22%. Although lidocaine treatment was well tolerated, a possible interaction with ciprofloxacin associated with side effects may occur upon concomitant administration.</p><p><em><u>Clozapine</u></em></p><p>Following concomitant administration of 250 mg ciprofloxacin with clozapine for 7 days, serum concentrations of clozapine and N-desmethylclozapine were increased by 29% and 31%, respectively. Clinical surveillance and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised (see section 4.4).</p><p><em><u>Sildenafil</u></em></p><p>Cmax and AUC of sildenafil were increased approximately twofold in healthy subjects after an oral dose of 50 mg given concomitantly with 500 mg ciprofloxacin. Therefore, caution should be used prescribing ciprofloxacin concomitantly with sildenafil taking into consideration the risks and the benefits.</p><p><em><u>Zolpidem</u></em></p><p>Co-administration of ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>The data that are available on administration of ciprofloxacin to pregnant women indicates no malformative or feto/neonatal toxicity of ciprofloxacin. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that the drug could cause damage to articular cartilage in the human immature organism / foetus (see section 5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of ciprofloxacin during</p><p>pregnancy.</p><p><strong>Lactation</strong></p><p>Ciprofloxacin is excreted in breast milk. Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its neurological effects, ciprofloxacin may affect reaction time. Thus, the ability to drive or to operate machinery may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong><u>Summary of safety:</u></strong></p><p>The most commonly reported adverse drug reactions (ADRs) are nausea and diarrhoea.</p><p>&nbsp;</p><p><strong>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong><u>Tabulated list of AE:</u></strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image2.png" o:spid="_x0000_s1030" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:220.5pt;
 margin-top:81.55pt;width:4.5pt;height:6pt;z-index:-16626688;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1029"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:294.7pt;margin-top:81.55pt;width:4.5pt;height:6pt;z-index:-16626176;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />ADRs derived from clinical studies and post-marketing surveillance with Floxacin (oral, intravenous, and sequential therapy) sorted by categories of frequency are listed below. The frequency analysis takes into account data from both oral and intravenous administration of ciprofloxacin.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Commo</strong><strong> </strong><strong>n</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>1/1 000 to</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>1/10 000 to &lt;</p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p>&lt; 1/10 000</p></td><td style="vertical-align:top"><p><strong>Frequency not known</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1/100</p><p>to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;</p><p>1/10</p></td><td style="vertical-align:top"><p>&lt; 1/100</p></td><td style="vertical-align:top"><p>1/1 000</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(cannot be estimated from available data)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and Infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Mycotic superinfectio ns</p></td><td style="vertical-align:top"><p>Antibiotic associated colitis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (very</p><p>rarely&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;with</p><p>possible fatal outcome) (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and Lymphatic System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Eosinophilia</p></td><td style="vertical-align:top"><p>Leukopenia Anaemia Neutropenia Leukocytosis Thrombocytope nia Thrombocytae mia</p></td><td style="vertical-align:top"><p>Haemolytic anaemia Agranulocyto sis Pancytopeni a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (life-</p><p>threatening) Bone marrow depression (life- threatening)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reaction Allergic oedema</p><p>/</p><p>angiooedema</p></td><td style="vertical-align:top"><p>Anaphylactic reaction Anaphylactic shock&nbsp;&nbsp;&nbsp;&nbsp; (life- threatening) (see section 4.4)</p><p>Serum sickness-like reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Hyperglycaemia Hypoglycaemia Hypoglycaemic</p><p>coma (see section</p><p>4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Psychomotor hyperactivity</p><p>/ agitation</p></td><td style="vertical-align:top"><p>Confusion&nbsp;&nbsp;&nbsp; and disorientation Anxiety reaction Abnormal dreams Depression</p></td><td style="vertical-align:top"><p>Psychotic reactions (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="_x0000_s1028" type="#_x0000_t75"
 style='position:absolute;margin-left:172pt;margin-top:80.35pt;width:4.5pt;
 height:6pt;z-index:-16625664;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:page'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page" anchory="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hallucinations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache Dizziness Sleep disorders Taste disorders</p></td><td style="vertical-align:top"><p>Par-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>Dysaesthesia Hypoaesthesia Tremor Seizures</p><p>(see section 4.4) Vertigo</p></td><td style="vertical-align:top"><p>Migraine Disturbed coordination Gait disturbance Olfactory nerve disorders Intracranial hypertension</p></td><td style="vertical-align:top"><p>Peripheral neuropath y&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (see</p><p>section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual disturbances</p></td><td style="vertical-align:top"><p>Visual colour distortions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</strong></p><p><strong>Labyrinth Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus Hearing loss / Hearing impaired</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ventricular arrhythmia</p><p>,QT</p><p>prolongati on, torsades de pointes</p><p>*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vasodilatation Hypotension Syncope</p></td><td style="vertical-align:top"><p>Vasculitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, Thoracic&nbsp;&nbsp; and Mediastinal Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea (including asthmatic condition)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointesti nal Disorders</strong></p></td><td style="vertical-align:top"><p>Nausea Diarrho ea</p></td><td style="vertical-align:top"><p>Vomiting Gastrointesti nal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</p><p>abdominal pains Dyspepsia Flatulence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increase in transaminase s</p></td><td style="vertical-align:top"><p>Hepatic impairment Cholestatic</p></td><td style="vertical-align:top"><p>Liver necrosis (very&nbsp;&nbsp;&nbsp; rarely</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased bilirubin</p></td><td style="vertical-align:top"><p>icterus Hepatitis</p></td><td style="vertical-align:top"><p>progressing to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life-</p><p>threatening hepatic failure) (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash Pruritus Urticaria</p></td><td style="vertical-align:top"><p>Photosensitivity reactions (see section 4.4)</p></td><td style="vertical-align:top"><p>Petechiae Erythema multiforme Erythema nodosum Stevens- Johnson syndrome (potentially life- threatening) Toxic epidermal necrolysis (potentially life- threatening)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskele tal, Connective Tissue&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and Bone Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Musculoskele tal pain (e.g. extremity pain,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back</p><p>pain,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain) Arthralgia</p></td><td style="vertical-align:top"><p>Myalgia Arthritis Increased muscle&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tone and cramping</p></td><td style="vertical-align:top"><p>Muscular weakness Tendinitis Tendon rupture (predominan tly&nbsp;&nbsp;&nbsp;&nbsp; Achilles tendon) (see section 4.4) Exacerbation of symptoms of myasthenia gravis&nbsp;&nbsp;&nbsp;&nbsp; (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and Urinary Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal impairment</p></td><td style="vertical-align:top"><p>Renal failure Haematuria Crystalluria (see section 4.4) Tubulointerstiti al nephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>General Disorders and Administratio n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Site</strong></p><p><strong>Conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthenia Fever</p></td><td style="vertical-align:top"><p>Oedema Sweating (hyperhidrosis)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in blood alkaline phosphatase</p></td><td style="vertical-align:top"><p>Prothrombin level abnormal Increased amylase</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* These events were reported during the postmarketing period and were observed predominantly among patients with further risk factors for QT prolongation (see section 4.4).</p><p><strong>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong><u>Other special population:</u></strong></p><p><em><u>Paediatric patients</u></em></p><p>The incidence of arthropathy, mentioned above, is referring to data collected in studies with adults. In children, arthropathy is reported to occur commonly (see section 4.4).</p><p><em><u>Geriatric patients</u></em></p><p>Should receive a dose selected according to the severity of the infection and the patient&#39;s creatinine clearance. (see 4.2)</p><p>-To report any side effect (s)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
  left:0;text-align:left;margin-left:84.5pt;margin-top:27.45pt;width:426.7pt;
  height:90.5pt;text-indent:0;z-index:-15722496;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page' filled="f"
  strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0in;margin-right:271.8pt;margin-bottom:
     0in;margin-left:5.4pt;margin-bottom:.0001pt;text-indent:0in;mso-list:l0 level1 lfo1;
     tab-stops:11.3pt'><![if !supportLists]><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><![endif]><span
     dir=LTR></span>The<span style='letter-spacing:-.3pt'> </span>National<span
     style='letter-spacing:-.6pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-2.35pt'> </span>Centre<span style='letter-spacing:
     -.25pt'> </span>(NPC):<o:p></o:p></p>
     <p class=MsoNormal style='margin-top:.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:11.25pt;margin-bottom:.0001pt;text-indent:-5.9pt;
     mso-list:l0 level1 lfo1;tab-stops:11.3pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>SFDA<span style='letter-spacing:
     -.25pt'> </span>Call<span style='letter-spacing:-.25pt'> </span>Center:<span
     style='letter-spacing:-.4pt'> </span>19999<o:p></o:p></p>
     <p class=MsoNormal style='margin-left:11.25pt;text-indent:-5.9pt;
     mso-list:l0 level1 lfo1;tab-stops:11.3pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>E-mail:<span
     style='letter-spacing:-.35pt'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoNormal style='margin-left:11.25pt;text-indent:-5.9pt;
     mso-list:l0 level1 lfo1;tab-stops:11.3pt'><![if !supportLists]><span
     style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:<span
     style='letter-spacing:-.35pt'> </span>https://ade.sfda.gov.sa<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="575" height="127" alt="Text Box: -	The National Pharmacovigilance Centre (NPC):
-	SFDA Call Center: 19999
-	E-mail: npc.drug@sfda.gov.sa
-	Website: https://ade.sfda.gov.sa
" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Saudi Arabia :</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC states /other countries</p><p><!--[if mso & !supportInlineShapes & supportFields]><span style='font-size:
10.0pt;mso-bidi-font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-font-family:
Calibri;mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:
AR-SA'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1026"
 type="#_x0000_t202" style='width:390.7pt;height:17.2pt;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001'
 filled="f" strokeweight=".48pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:1.3pt;margin-right:0in;margin-bottom:
    0in;margin-left:5.35pt;margin-bottom:.0001pt'><span style='letter-spacing:
    -.05pt'>-Please</span><span style='letter-spacing:-.65pt'> </span><span
    style='letter-spacing:-.05pt'>contact</span><span style='letter-spacing:
    -.45pt'> </span>the<span style='letter-spacing:-.35pt'> </span>relevant<span
    style='letter-spacing:-.3pt'> </span>competent<span style='letter-spacing:
    -.1pt'> </span>authority.<o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="527" height="28" alt="Text Box: -Please contact the relevant competent authority." src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;font-family:"Calibri",sans-serif;
mso-fareast-font-family:Calibri;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><v:shape id="_x0000_i1025" type="#_x0000_t75"
 style='width:390.7pt;height:17.2pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An overdose of 12 g has been reported to lead to mild symptoms of toxicity. An acute overdose of 16 g has been reported to cause acute renal failure.</p><p>Symptoms in overdose consist of dizziness, tremor, headache, tiredness, seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria and haematuria. Reversible renal toxicity has been reported.</p><p>Apart from routine emergency measures, it is recommended to monitor renal function, including urinary pH and acidify, if required, to prevent crystalluria. Patients should be kept well hydrated.</p><p>Only a small quantity of ciprofloxacin (&lt;10%) is eliminated by haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Fluoroquinolones, ATC code: J01MA02</p><p><em><u>Mechanism of action:</u></em></p><p>As a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.</p><p><em><u>PK/PD relationship:</u></em></p><p>Efficacy mainly depends on the relation between the maximum concentration in serum (Cmax) and the minimum inhibitory concentration (MIC) of ciprofloxacin for a bacterial pathogen and the relation between the area under the curve (AUC) and the MIC.</p><p><em><u>Mechanism of resistance:</u></em></p><p>In-vitro <em>resistance to ciprofloxacin can be acquired through a stepwise process by target site mutations in both DNA gyrase and topoisomerase IV. The degree of cross- resistance between ciprofloxacin and other fluoroquinolones that results is variable. Single mutations may not result in clinical resistance, but multiple mutations generally result in clinical resistance to many or all active substances within the class. Impermeability and/or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance. All </em>in-vitro <em>mechanisms of resistance are commonly observed in clinical isolates. Resistance mechanisms that inactivate other antibiotics such as permeation barriers (common in </em>Pseudomonas aeruginosa<em>) and efflux mechanisms may affect susceptibility to ciprofloxacin.</em></p><p><em>Plasmid-mediated resistance encoded by qnr-genes has been reported. <u>Spectrum of antibacterial activity:</u></em></p><p>Breakpoints separate susceptible strains from strains with intermediate susceptibility and the latter from resistant strains:</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image3.png" o:spid="_x0000_s1034" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:250.35pt;
 margin-top:44.4pt;width:4.45pt;height:5.95pt;z-index:-16624128;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1033"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:250.35pt;margin-top:66.5pt;width:4.45pt;height:5.95pt;z-index:-16623616;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1032"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:250.35pt;margin-top:88.65pt;width:4.45pt;height:5.95pt;z-index:-16623104;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1031"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:250.35pt;margin-top:110.8pt;width:4.45pt;height:5.95pt;z-index:-16622592;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><em><u>EUCAST Recommendations</u></em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Microorganisms</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteria</em></p></td><td style="vertical-align:top"><p>S&nbsp;&nbsp;&nbsp;&nbsp; 0.5 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas</em></p></td><td style="vertical-align:top"><p>S&nbsp;&nbsp;&nbsp;&nbsp; 0.5 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter</em></p></td><td style="vertical-align:top"><p>S&nbsp;&nbsp;&nbsp;&nbsp; 1 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus </em>spp.<sup>1</sup></p></td><td style="vertical-align:top"><p>S&nbsp;&nbsp;&nbsp;&nbsp; 1 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae </em>and</p><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>S&nbsp;&nbsp;&nbsp;&nbsp; 0.5 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria</em><em> </em><em>gonorrhoeae</em></p></td><td style="vertical-align:top"><p>S&nbsp;&nbsp;&nbsp;&nbsp; 0.03 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria meningitidis</em></p></td><td style="vertical-align:top"><p>S&nbsp;&nbsp;&nbsp;&nbsp; 0.03 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Non-species-related</p></td><td style="vertical-align:top"><p>S&nbsp;&nbsp;&nbsp;&nbsp; 0.5 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>breakpoints<strong>*</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>1 <em>Staphylococcus </em>spp. - breakpoints for ciprofloxacin relate to high dose therapy.</p><p>* Non-species-related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and not for those species where susceptibility testing is not recommended.</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>Groupings of relevant species&nbsp; &nbsp;according&nbsp; &nbsp;to&nbsp; &nbsp;ciprofloxacin&nbsp; &nbsp;susceptibility&nbsp; &nbsp;(for</p><p><em>Streptococcus </em>species see section 4.4)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>COMMONLY SUSCEPTIBLE SPECIES</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Bacillus anthracis </em>(1)</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Aeromonas </em>spp.</p><p><em>Brucella </em>spp. <em>Citrobacter koseri Francisella tularensis Haemophilus ducreyi</em></p><p><em>Haemophilus influenzae*</em><em> </em><em>Legionella </em>spp.</p><p><em>Moraxella catarrhalis* Neisseria meningitidis Pasteurella </em>spp.</p><p><em>Salmonella </em>spp.<em>* Shigella </em>spp.<em>* Vibrio </em>spp.</p><p><em>Yersinia pestis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Mobiluncus</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Other micro-organisms</u> <em>Chlamydia trachomatis </em>($) <em>Chlamydia pneumoniae </em>($) <em>Mycoplasma hominis </em>($) <em>Mycoplasma pneumoniae </em>($)</p></td></tr><tr><td style="vertical-align:top"><p><strong>SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u> <em>Enterococcus faecalis </em>($) <em>Staphylococcus </em>spp.<em>* </em>(2)</p></td></tr></tbody></table><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="image2.png" o:spid="_x0000_s1030"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:176.25pt;margin-top:645.6pt;width:4.5pt;height:6pt;z-index:-16619520;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:page'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
 <w:wrap anchorx="page" anchory="page"/>
</v:shape><![endif]--><img width="6" height="8" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1028"
 style='width:422.65pt;height:.25pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="8453,5">
 <v:rect id="_x0000_s1029" style='position:absolute;width:8453;height:5'
  fillcolor="#9f9f9f" stroked="f"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:422.65pt;height:.25pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter </em><em>baumannii<sup>+</sup> Burkholderia cepacia<sup>+</sup> * Campylobacter </em>spp.<em><sup>+</sup> * Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae* Escherichia coli* Klebsiella oxytoca Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae* Proteus mirabilis* Proteus vulgaris* Providencia </em>spp.</p><p><em>Pseudomonas </em><em>aeruginosa*</em><em> </em><em>Pseudomonas fluorescens Serratia marcescens*</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Peptostreptococcus </em>spp.</p><p><em>Propionibacterium acnes</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>INHERENTLY RESISTANT ORGANISMS</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Actinomyces Enteroccus faecium Listeria monocytogenes</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Excepted as listed above</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Other micro-organisms</u> <em>Mycoplasma genitalium Ureaplasma urealitycum</em></p></td></tr><tr><td style="vertical-align:top"><p>* Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications</p><p><sup>+</sup> Resistance rate 50% in one or more EU countries</p><p>($): Natural intermediate susceptibility in the absence of acquired mechanism of resistance</p><p>(1): Studies have been conducted in experimental animal infections due to inhalations of <em>Bacillus anthracis </em>spores; these studies reveal that antibiotics starting early after exposition avoid the occurrence of the disease if the treatment is made up to the decrease of the number of spores in the organism under the infective dose. The recommended use in human subjects is based primarily on <em>in-vitro </em>susceptibility</p></td></tr></tbody></table><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1026"
 style='width:422.65pt;height:.25pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="8453,5">
 <v:rect id="_x0000_s1027" style='position:absolute;width:8453;height:5'
  fillcolor="#9f9f9f" stroked="f"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1026"
 type="#_x0000_t75" style='width:422.65pt;height:.25pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>and on animal experimental data together with limited human data. Two-month treatment duration in adults with oral ciprofloxacin given at the following dose, 500 mg bid, is considered as effective to prevent anthrax infection in humans. The treating physician should refer to national and/or international consensus documents regarding treatment of anthrax.</p><p>(2): Methicillin-resistant <em>S. aureus </em>very commonly express co-resistance to fluoroquinolones. The rate of resistance to methicillin is around 20 to 50% among all staphylococcal species and is usually higher in nosocomial isolates.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Absorption</u></em></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image1.png" o:spid="_x0000_s1038" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:401.45pt;
 margin-top:35.55pt;width:4.2pt;height:.7pt;z-index:-16618496;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />Following oral administration of single doses of 250 mg, 500 mg, and 750 mg of ciprofloxacin tablets, ciprofloxacin is absorbed rapidly and extensively, mainly from the small intestine, reaching maximum serum concentrations 1 2 hours later.</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1037" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:231.85pt;margin-top:6.25pt;width:4.5pt;height:.75pt;
 z-index:-16615936;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />Single doses of 100 750 mg produced dose-dependent maximum serum concentrations (Cmax) between 0.56 and 3.7 mg/L. Serum concentrations increase proportionately with doses up to 1000 mg.</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1036"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:325.5pt;margin-top:6pt;width:4.2pt;height:.7pt;z-index:-16617984;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />The absolute bioavailability is approximately 70 80%.</p><p>A 500 mg oral dose given every 12 hours has been shown to produce an area under the serum concentration-time curve (AUC) equivalent to that produced by an intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every 12 hours. <em><u>Distribution</u></em></p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1035" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:301.1pt;margin-top:6.15pt;width:4.2pt;height:.7pt;
 z-index:-16617472;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /><!--[if gte vml 1]><v:shape id="_x0000_s1034"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:492.85pt;margin-top:20.8pt;width:4.2pt;height:.7pt;z-index:-16616960;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />Protein binding of ciprofloxacin is low (20 30%). Ciprofloxacin is present in plasma largely in a non-ionised form and has a large steady state distribution volume of 2 3 L/kg body weight. Ciprofloxacin reaches high concentrations in a variety of tissues such as lung (epithelial fluid, alveolar macrophages, biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine, prostate, endometrium) where total concentrations exceeding those of plasma concentrations are reached.</p><p><em><u>Metabolism</u></em></p><p>Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M 1), sulphociprofloxacin (M 2), oxociprofloxacin (M 3) and formylciprofloxacin (M 4). The metabolites display <em>in-vitro </em>antimicrobial activity but to a lower degree than the parent compound.</p><p>Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.</p><p><em><u>Elimination</u></em></p><p><!--[if gte vml 1]><v:shape id="_x0000_s1033"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:173.3pt;margin-top:35.35pt;width:3.9pt;height:.65pt;z-index:-16616448;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="5" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg" />Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally. The serum elimination half-life in subjects with normal renal function is approximately 4 7 hours.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Excretion of ciprofloxacin (% of dose)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Oral Administration</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Urine</strong></p></td><td style="vertical-align:top"><p><strong>Faeces</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ciprofloxacin</p></td><td style="vertical-align:top"><p>44.7</p></td><td style="vertical-align:top"><p>25.0</p></td></tr><tr><td style="vertical-align:top"><p>Metabolites (M1 -M4 )</p></td><td style="vertical-align:top"><p>11.3</p></td><td style="vertical-align:top"><p>7.5</p></td></tr></tbody></table><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1032" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:261.1pt;margin-top:7.65pt;width:4.2pt;height:.7pt;
 z-index:-16615424;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /><!--[if gte vml 1]><v:shape id="_x0000_s1031"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:159.05pt;margin-top:22.3pt;width:4.2pt;height:.7pt;z-index:-16614912;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />Renal clearance is between 180 300 mL/kg/h and the total body clearance is between 480 600 mL/kg/h. Ciprofloxacin undergoes both glomerular filtration and tubular secretion. Severely impaired renal function leads to increased half lives of ciprofloxacin of up to 12 h.</p><p>Non-renal clearance of ciprofloxacin is mainly due to active trans-intestinal secretion and metabolism. 1% of the dose is excreted via the biliary route. Ciprofloxacin is present in the bile in high concentrations.</p><p><em><u>Paediatric patients</u></em></p><p>The pharmacokinetic data in paediatric patients are limited.</p><p>In a study in children Cmax and AUC were not age-dependent (above one year of age). No notable increase in Cmax and AUC upon multiple dosing (10 mg/kg three times daily) was observed.</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1030" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:402.25pt;margin-top:6pt;width:4.2pt;height:.7pt;
 z-index:-16614400;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />In 10 children with severe sepsis Cmax was 6.1 mg/L (range 4.6 8.3 mg/L) after a 1- hour intravenous infusion of 10 mg/kg in children aged less than 1 year compared to</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1029" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:190pt;margin-top:6.05pt;width:3.9pt;
 height:.65pt;z-index:-16613888;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="5" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg" /><!--[if gte vml 1]><v:shape id="_x0000_s1028"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:277.25pt;margin-top:20.7pt;width:3.9pt;height:.65pt;z-index:-16613376;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="5" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg" /><!--[if gte vml 1]><v:shape id="_x0000_s1027"
 type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
 margin-left:499pt;margin-top:20.7pt;width:3.9pt;height:.65pt;z-index:-16612864;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="5" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg" />7.2 mg/L (range 4.7 11.8 mg/L) for children between 1 and 5 years of age. The AUC values were 17.4 mg*h/L (range 11.8 32.0 mg*h/L) and 16.5 mg*h/L (range 11.0</p><p>23.8 mg*h/L) in the respective age groups.</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
 margin-left:343.25pt;margin-top:35.25pt;width:4.2pt;height:.7pt;z-index:-16612352;
 visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
 mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="6" height="1" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />These values are within the range reported for adults at therapeutic doses. Based on population pharmacokinetic analysis of paediatric patients with various infections, the predicted mean half-life in children is approx. 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 hours and the bioavailability of the oral suspension ranges from 50 to 80%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazards for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential, or toxicity to reproduction.</p><p>Like a number of other quinolones, ciprofloxacin is phototoxic in animals at clinically relevant exposure levels. Data on photomutagenicity/ photocarcinogenicity show a weak photomutagenic or phototumorigenic effect of ciprofloxacin <em>in-vitro </em>and in animal experiments. This effect was comparable to that of other gyrase inhibitors.</p><p>Articular tolerability:</p><p>As reported for other gyrase inhibitors, ciprofloxacin causes damage to the large weight-bearing joints in immature animals. The extent of the cartilage damage varies according to age, species and dose; the damage can be reduced by taking the weight off the joints. Studies with mature animals (rat, dog) revealed no evidence of cartilage lesions. In a study in young beagle dogs, ciprofloxacin caused severe articular changes at therapeutic doses after two weeks of treatment, which were still observed after 5 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Avicel PH 102</p><p>Corn Starch</p><p>Croscarmellose sodium</p><p>Polysorbate 80</p><p>Povidone k30</p><p>Sodium Starch Glycolate</p><p>Talc</p><p>Aerosil</p><p>Mg stearate</p><p>Opadry white</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Forming PVC / Aluminum blister pack. Packs of 10 film-coated tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited Jeddah – Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>